<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Statin muscle-related adverse events</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Statin muscle-related adverse events</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Statin muscle-related adverse events</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Rosenson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven K Baker, MSc, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mason W Freeman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sara Swenson, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H846533837"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Statins are the primary class of medication used to lower serum cholesterol concentration for both primary and secondary prevention of cardiovascular disease. (See  <a class="medical medical_review" href="/d/html/4549.html" rel="external">"Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a>.)</p><p>Statins are both effective and generally safe. Although muscle toxicity remains a concern, severe myonecrosis leading to clinical rhabdomyolysis is rare, affecting perhaps 0.1 percent of patients [<a href="#rid1">1,2</a>]. Muscle syndromes associated with statins include myalgias, myopathy, myositis, and muscle injury [<a href="#rid3">3,4</a>]. The clinical and distinct histopathological findings of these syndromes are presented in the table  (<a class="graphic graphic_table graphicRef115539" href="/d/graphic/115539.html" rel="external">table 1</a>). Other statin side effects are discussed separately. (See  <a class="medical medical_review" href="/d/html/4564.html" rel="external">"Statins: Actions, side effects, and administration"</a>.)</p><p class="headingAnchor" id="H107312583"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The mechanism by which statins cause muscle toxicity or statin-associated muscle symptoms (SAMS) is not well understood, and the term SAMS is used to imply that these symptoms are not always truly caused by statin use. Nevertheless, progress is being made in understanding the causal relationships, including genetic studies [<a href="#rid5">5,6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Candidate gene studies – Examples include genes that play a role in SAMS through their impact on statin metabolism, transport, or action. These genes include variation in cytochrome P450 genes including <em>CYP3A4</em>, <em>CYP3A5</em>, <em>CYP2D6</em>, and the vitamin D receptor gene.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genome-wide association studies – Examples include <em>SLCO1B1</em> rs4149056 and other variants. The <em>SLCO1B1</em> gene product is responsible for hepatic uptake of statins. Loss of function variant rs4149056 is associated with higher plasma levels of statins, in particular <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a> and to a lesser extent <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a>, leading to greater systemic exposure including at the level of muscle.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Human leukocyte antigen basis for statin-associated necrotizing myopathy – An example is the condition of statin-associated autoimmune myopathy that results from autoantibodies that recognize hydroxymethylglutaryl (HMG)-CoA reductase (HMGCR). These antibodies may have a direct effect on muscle tissue expressing HMGCR, resulting in myalgia, myopathy, myonecrosis (creatine kinase [CK] levels &gt;1000 international units/L), and prominent myofiber necrosis on muscle biopsy [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multi-omic networks – These are studies of genes related to proteomics, lipidomics, etc, which contribute to the transcription, metabolism, and metabolite levels and which may be related to SAMS.</p><p></p><p>Individual statins may have distinct effects on the synthesis of Coenzyme Q10 (CoQ10, ubiquinone), which plays an important role in muscle cell energy production. It has been speculated that a reduction in ubiquinone in skeletal muscle may contribute to statin-induced muscle injury. Some studies have found that statins decrease skeletal muscle and plasma concentrations of ubiquinone [<a href="#rid7">7-10</a>]; however, other studies have not [<a href="#rid11">11</a>], and studies have come to different conclusions about whether statin treatment decreases levels of ubiquinone in skeletal muscle [<a href="#rid9">9,12,13</a>]. Long-term treatment with <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a> (10 to 40 mg/day for &gt;12 months) reduced ubiquinone content in skeletal muscles and decreased maximal mitochondrial oxidative phosphorylation capacity [<a href="#rid14">14</a>].</p><p>One study found increased levels of plant sterols in skeletal muscle in patients treated with high-dose statins [<a href="#rid9">9</a>]. Specifically, sitosterol was increased by approximately 50 percent. The authors of the study proposed that these increased cellular levels could contribute to the muscle toxicity of statins. Beta-sitosterol is an activator of AMP-activated protein kinase, which inhibits acetyl-CoA carboxylase. This results in reduced fat synthesis and increased beta-oxidation. Preliminary evidence suggests that statin-intolerant patients demonstrate increased fatty acid oxidation (FAO) in response to <a class="drug drug_general" data-topicid="9575" href="/d/drug information/9575.html" rel="external">lovastatin</a>, implicating an intrinsic FAO abnormality [<a href="#rid15">15</a>]. Statins increase the expression of mitochondrial carnitine acylcarnitine translocase, and this effect may contribute to the alteration in FAO [<a href="#rid16">16</a>].</p><p>Atrogin-1, a muscle-specific ubiquitin protein ligase, may play an important role in statin toxicity. <a class="drug drug_general" data-topicid="9575" href="/d/drug information/9575.html" rel="external">Lovastatin</a> induces expression of atrogin-1 in humans with statin myopathy and in several in vitro models; in the models, myopathy could be prevented by knockdown of atrogin-1 [<a href="#rid17">17</a>]. These and other proposed mechanisms require further experimental confirmation.</p><p>Among patients experiencing statin-induced myalgia, skeletal muscle gene expression data show that persistent myalgia may result from cellular stress that results from mechanisms of post-inflammatory repair and end-organ susceptibility. The genetic basis for SAMS is supported by an increased frequency of single-nucleotide polymorphisms that were found in patients with statin myalgia  (<a class="graphic graphic_figure graphicRef115538" href="/d/graphic/115538.html" rel="external">figure 1</a>) [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H10919350"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>Terminology around statin-associated adverse muscle events is variable and has changed over time [<a href="#rid5">5,19</a>]. In this topic, where possible, we use the categories of events defined by the 2014 National Lipid Association Statin Muscle Safety Task Force [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myalgia</strong> – A symptom of muscle-discomfort, including muscle aches, soreness, stiffness, tenderness, or cramps with or soon after exercise, with a normal creatine kinase (CK) level. Myalgia symptoms can be described as similar to what would be experienced with a viral syndrome such as influenza.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myopathy</strong> – Muscle weakness (not due to pain), with or without an elevation in CK level.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myositis</strong> – Muscle inflammation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myonecrosis</strong> – Elevation in muscle enzymes compared with either baseline CK levels (while not on statin therapy) or the upper limit of normal that has been adjusted for age, race, and sex:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mild – Three- to 10-fold elevation in CK</p><p class="bulletIndent2"><span class="glyph">•</span>Moderate – 10- to 50-fold elevation in CK</p><p class="bulletIndent2"><span class="glyph">•</span>Severe – 50-fold or greater elevation in CK</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical rhabdomyolysis</strong> – Defined by the Task Force as myonecrosis with myoglobinuria or acute renal failure (an increase in serum creatinine of at least 0.5 mg/dL [44 micromol/L]).</p><p></p><p class="headingAnchor" id="H639419888"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Information about muscle injury and statins has come both from large clinical trials of statin therapy and from observational studies of statins in clinical use [<a href="#rid20">20</a>]. Often, research definitions require that the muscle symptoms be accompanied by elevations in creatine kinase, which excludes the more common definition of myalgia and myopathy used in other trials [<a href="#rid4">4</a>].</p><p>Using a strict definition, a 2014 meta-analysis of 42 randomized trials of statins found little or no excess risk of myalgias, creatine kinase (CK) elevations, rhabdomyolysis, or discontinuation of therapy versus placebo [<a href="#rid21">21</a>]. A small increase in muscle symptoms was found in a 2022 meta-analysis of 19 large trials, in which 27.1 percent of participants treated with a statin reported at least one episode of muscle pain or weakness during a median of 4.3 years, compared with 26.6 percent of participants treated with placebo (rate ratio 1.03, 95% CI 1.01-1.06) [<a href="#rid22">22</a>]. There was also a small increase in muscle pain or weakness among those treated with more intensive versus less intensive statin treatment (ie, 40 to 80 mg <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a> or 20 to 40 mg <a class="drug drug_general" data-topicid="10282" href="/d/drug information/10282.html" rel="external">rosuvastatin</a> daily).</p><p>Experience in clinical practice suggests that muscle side effects are relatively common, including side effects requiring discontinuation of statin therapy. The explanation for this difference is uncertain, but it may relate to selection criteria in randomized trials that limit the ability to generalize their results to the side effect profiles seen in a broader population of patients [<a href="#rid23">23</a>]. </p><p>Consistent with this, a 2013 six-month randomized trial in 420 healthy adults designed to examine the effects of statin therapy on muscle function found a higher incidence of myalgia in patients treated with <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a> 80 mg/day than with placebo (9.3 versus 4.6 percent) [<a href="#rid24">24</a>].</p><p>Clinically significant myonecrosis, defined as a serum CK elevation more than 10 times normal in association with muscle symptoms, occurred in less than 0.5 percent of patients in large clinical trials [<a href="#rid25">25-28</a>]. A review of one year of records for 1014 patients taking statins in a primary care practice found that 0.9 percent of patients had CK elevations more than five times normal, and none of these appeared to be related to statin use [<a href="#rid29">29</a>]. Fourteen patients (2.1 percent) had elevations 2.5 to 5.0 times normal, and of these two appeared to be potentially related to statin use.</p><p>In large clinical trials, massive rhabdomyolysis with acute renal failure was not seen in patients who did not have other risk factors. Rhabdomyolysis has primarily been seen when a statin is given concurrently with <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="8488" href="/d/drug information/8488.html" rel="external">gemfibrozil</a>, or protease inhibitors [<a href="#rid30">30-32</a>] (see <a class="local">'Concurrent drug therapy'</a> below). In addition, there have been case reports of rhabdomyolysis in patients taking statins in combination with <a class="drug drug_general" data-topicid="9695" href="/d/drug information/9695.html" rel="external">niacin</a>, macrolide antibiotics, <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a>, antifungal medications, and <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid33">33,34</a>].</p><p>One study examined claims data from 11 managed care plans that included 252,460 patients treated with lipid-lowering agents [<a href="#rid2">2</a>]. The average incidence of hospitalization for rhabdomyolysis was 0.44 per 10,000 patient-years (95% CI 0.20-0.84) for patients treated with <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a>, <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">pravastatin</a>, or <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a> monotherapy. Although the study did not find a statistical difference in the incidence of rhabdomyolysis among these three statins, no cases of rhabdomyolysis were seen with pravastatin. The incidence was higher with cerivastatin monotherapy (5.34 per 10,000 patient-years), and this statin was ultimately withdrawn from the market.</p><p>Many individuals who are prescribed statins discontinue treatment due to perceived side effects [<a href="#rid35">35</a>]. An internet-based survey that included 10,138 respondents (88 percent current statin users, 12 percent former users) found that the primary reason for discontinuation of statin therapy was side effects [<a href="#rid36">36</a>]. Muscle-related side effects were reported by 60 percent of former users and 25 percent of current users. However, the study did not make it clear whether the temporal relation between symptoms and starting or stopping statin therapy was assessed, and it is uncertain whether the 25 percent of current users with muscle symptoms attributed those symptoms to their therapy. Concomitant use of medications that inhibit statin metabolism increased the risk for muscle symptoms and for discontinuation of statin therapy for such symptoms [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H107312605"><span class="h1">RISK FACTORS</span></p><p class="headingAnchor" id="H107312612"><span class="h2">Statin characteristics</span><span class="headingEndMark"> — </span>The ability to cause muscle injury appears to vary among the different statins and according to statin dose.</p><p>The risk of myopathy appears to be lowest with <a class="drug drug_general" data-topicid="8473" href="/d/drug information/8473.html" rel="external">fluvastatin</a>, <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">pravastatin</a>, and <a class="drug drug_general" data-topicid="9532" href="/d/drug information/9532.html" rel="external">pitavastatin</a> [<a href="#rid38">38,39</a>]. Possible reasons are described below:</p><p class="bulletIndent1"><span class="glyph">●</span>These statins are not metabolized by cytochrome P450 3A4 (CYP3A4) and are thus less likely to be involved with drug interactions [<a href="#rid4">4,40</a>]. (See <a class="local">'Drug interactions'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the case of <a class="drug drug_general" data-topicid="8473" href="/d/drug information/8473.html" rel="external">fluvastatin</a>, the lower risk may be related to the much lower systemic exposure of the extended-release formulation [<a href="#rid41">41</a>].</p><p></p><p>The risk of muscle injury is substantially increased when taking statins extensively metabolized by CYP3A4 such as <a class="drug drug_general" data-topicid="9575" href="/d/drug information/9575.html" rel="external">lovastatin</a>, <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a>, and <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a>.</p><p>For all statins, the risk of muscle injury is greater at higher doses. With <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a>, for example, the incidence of myositis in clinical trials was 0.02 percent at 20 mg/day, 0.07 percent at 40 mg/day, and 0.3 percent at 80 mg/day [<a href="#rid42">42</a>]. (See <a class="local">'Dose limitations'</a> below.)</p><p>The safety of <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">pravastatin</a> (40 mg/day) was confirmed in an analysis of more than 112,000 patient-years of experience in three large trials [<a href="#rid43">43</a>]. The incidence of serum creatine kinase (CK) elevations was not different from placebo, and there were no cases of confirmed clinical myositis or rhabdomyolysis. In an observational study of over 7000 patients on high-dose statin therapy, <a class="drug drug_general" data-topicid="8473" href="/d/drug information/8473.html" rel="external">fluvastatin</a> had the lowest rate of muscle symptoms among the statins [<a href="#rid38">38</a>]. <a class="drug drug_general" data-topicid="9532" href="/d/drug information/9532.html" rel="external">Pitavastatin</a> is not catabolized by CYP3A4 and also has a low risk of muscle injury [<a href="#rid39">39</a>].</p><p>The safety of <a class="drug drug_general" data-topicid="10282" href="/d/drug information/10282.html" rel="external">rosuvastatin</a> was demonstrated in a trial in 17,802 apparently healthy adults, in which rates of muscle toxicity with rosuvastatin 20 mg/day were similar to placebo [<a href="#rid44">44</a>]. However, there have been reports of rhabdomyolysis with rosuvastatin, particularly in myopathy-prone patients treated with doses higher than those recommended by the US Food and Drug Administration (FDA) product labeling, and product labeling in Europe highlights this risk, particularly at the highest dose of 40 mg/day [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H107312679"><span class="h2">Preexisting neuromuscular disorders</span><span class="headingEndMark"> — </span>Underlying neuromuscular disorders may interact with statin therapy. In some cases, statins can cause new neuromuscular disorders (see <a class="local">'Neuromuscular disorders'</a> below); however, others involve increased risk of toxicity in patients with known underlying neuromuscular disorders or the development of clinically apparent disease in patients who had likely had preclinical disease before statins were initiated.</p><p>Statins appear to have deleterious effects in patients with amyotrophic lateral sclerosis (ALS) and conditions that mimic ALS [<a href="#rid46">46</a>]. Cholesterol levels may play an important role, as dyslipidemia has been associated with prolonged survival in ALS [<a href="#rid47">47</a>]. ALS-associated hypermetabolism may require more cholesterol availability. Indeed, calorie restriction exacerbates motor symptoms and high fat intake improves survival in a mouse model of ALS [<a href="#rid48">48</a>]. Sterol bioavailability and cholesterol synthesis represent pivotal adaptive responses to extracellular stress [<a href="#rid49">49</a>]. Although the optimal lipid levels are unknown for patients with ALS, it is considered reasonable to withdraw statins and other hypolipidemics in patients who develop ALS.</p><p>For genetically based muscle disorders, statins are believed to trigger myogenic symptoms more readily than in healthy subjects due to a reduced ability to compensate for drug-induced myotoxicity. In such patients, myopathic symptoms often persist after statin withdrawal, and this is a clinical indicator for electromyography and, potentially, muscle biopsy. It seems likely that the diverse neuromuscular phenotypes associated with statin use reflect multiple mechanisms acting either singly or synergistically.</p><p>Reports of diseases that have become clinically apparent in patients on statins include myasthenia gravis [<a href="#rid50">50,51</a>], mitochondrial myopathy [<a href="#rid52">52-54</a>], McArdle disease [<a href="#rid54">54-56</a>], acid maltase deficiency [<a href="#rid57">57</a>], muscle phosphorylase b kinase deficiency [<a href="#rid58">58</a>], carnitine-palmitoyl transferase deficiency [<a href="#rid59">59</a>], rippling muscle disease (RMD) [<a href="#rid60">60</a>], myotonic dystrophy types 1 and 2 [<a href="#rid54">54,61</a>], cytoplasmic- and hyaline-body (myosin storage) myopathies [<a href="#rid62">62,63</a>], motor neuronopathies (eg, Kennedy disease [<a href="#rid54">54</a>] and ALS [<a href="#rid46">46</a>]), dermatomyositis/polymyositis, inclusion body myositis, carnitine palmitoyltransferase II (CPT2) deficiency, and myoadenylate deaminase deficiency [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H107314231"><span class="h2">Hypothyroidism, hypovitaminosis D, and other disorders</span><span class="headingEndMark"> — </span>Enhanced susceptibility to statin-associated myopathy occurs in patients with hypothyroidism, acute or chronic renal failure, and obstructive liver disease. In one hypothyroid patient, the myopathy resolved promptly after discontinuation of <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">pravastatin</a> and before initiation of thyroid hormone replacement [<a href="#rid64">64</a>], but in a second case the myopathy persisted until thyroid hormone was replaced [<a href="#rid65">65</a>]. These reports suggest that hypothyroidism may predispose to the development of statin-associated myopathy and that use of statins may "unmask" hypothyroid myopathy (see  <a class="medical medical_review" href="/d/html/4837.html" rel="external">"Hypothyroid myopathy"</a>). Very low vitamin D levels have been associated with higher rates of myalgia and myopathy. Replenishing low vitamin D levels can be an effective approach to improving statin tolerance in some patients with prior statin-associated muscle symptoms (SAMS) [<a href="#rid66">66-68</a>].</p><p class="headingAnchor" id="H107312686"><span class="h2">Patient characteristics</span><span class="headingEndMark"> — </span>Genetic factors appear to increase the risk of statin myopathy [<a href="#rid69">69</a>]. A genome-wide association study found that common variants of the <em>SLCO1B1</em> gene, which encodes the organic anion transporting polypeptide 1B1 (OATP1B1) that mediates hepatic uptake of most statins, substantially increased or decreased the risk of myopathy in patients treated with <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a> [<a href="#rid70">70</a>]. A subsequent trial of statins found an association between a specific <em>SLCO1B1</em> variant (SLCO1B1*5) and an increased risk of mild adverse events [<a href="#rid71">71</a>]. Testing for <em>SLCO1B1</em> variants associated with statin myopathy is commercially available, but it seems unlikely that such a test would be clinically useful or worth the expense in most situations.</p><p>As discussed, it remains unclear whether lipid-soluble statins penetrate the muscle membrane more readily than water-soluble statins, leading to increased risk for myopathy (see <a class="local">'Statin characteristics'</a> above). The discovery that organic anion transport polypeptide 2B1 (SLCO2B1) is expressed on the sarcolemma and mediates uptake of statins into the myocyte argues against a significant pathogenic role for passive diffusion of the fat-soluble statins. In addition to <em>SLCO2B1</em>, the multidrug resistance-associated proteins MRP1, MRP4, and MRP5 are also present in skeletal muscle and function as statin efflux transporters [<a href="#rid72">72</a>]. Ongoing research may clarify additional risk factors for myopathy related to statin transport phenomena in and out of skeletal muscle.</p><p>Certain racial populations may be at increased risk for statin myopathy, at least with <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a>. Simvastatin prescribing information recommends caution when doses above 20 mg/day are used in Chinese patients who are also receiving <a class="drug drug_general" data-topicid="9695" href="/d/drug information/9695.html" rel="external">niacin</a> and states that such patients should not be treated with simvastatin 80 mg/day in combination with niacin [<a href="#rid73">73</a>]. In a large randomized trial in which all patients were treated with simvastatin 40 mg/day, participants from China had a higher rate of myopathy than patients from Europe (1.3 versus 0.4 events per 1000 patients per year) [<a href="#rid74">74</a>]. This risk was increased further in Chinese patients randomly assigned to treatment with niacin/laropiprant rather than placebo (risk ratio [RR] 5.2 versus 1.5 in European patients). Of note, we suggest not treating any patients with simvastatin at doses above 40 mg/day even when used as monotherapy. (See  <a class="medical medical_review" href="/d/html/4564.html" rel="external">"Statins: Actions, side effects, and administration", section on 'Potency'</a>.)</p><p>Other patient factors associated with an increased risk of statin-associated adverse muscle events include advanced age (greater than 80 years), frailty, female sex, small body frame, acute or decompensated liver disease, and severe renal disease [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H107312713"><span class="h2">Concurrent drug therapy</span><span class="headingEndMark"> — </span>The increase in susceptibility to myopathy is substantially greater in patients receiving concurrent therapy with a number of drugs, particularly those that inhibit CYP3A4  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 2</a>) [<a href="#rid76">76</a>], as well as with fibrates [<a href="#rid77">77</a>]. Furthermore, concurrent use of a drug or drug class that is independently considered a risk factor for myopathy (ie, glucocorticoids, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9304" href="/d/drug information/9304.html" rel="external">daptomycin</a>, <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a>, and <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>) may further increase risk [<a href="#rid34">34,78,79</a>]. Although initial studies described cases of myopathy when <a class="drug drug_general" data-topicid="9695" href="/d/drug information/9695.html" rel="external">niacin</a> (nicotinic acid) was given with a statin [<a href="#rid80">80</a>], this complication appears to be uncommon [<a href="#rid81">81-83</a>].</p><p>The uptake, metabolism, and clearance of each statin differs, and therefore each statin is subject to different types of drug interactions.</p><p><a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">Simvastatin</a>, <a class="drug drug_general" data-topicid="9575" href="/d/drug information/9575.html" rel="external">lovastatin</a>, and to a lesser extent <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a> are metabolized by CYP3A4. <a class="drug drug_general" data-topicid="8473" href="/d/drug information/8473.html" rel="external">Fluvastatin</a> clearance is partly dependent upon CYP2C9 metabolism whereas <a class="drug drug_general" data-topicid="10282" href="/d/drug information/10282.html" rel="external">rosuvastatin</a>, <a class="drug drug_general" data-topicid="9532" href="/d/drug information/9532.html" rel="external">pitavastatin</a>, and <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">pravastatin</a> are cleared primarily by non-CYP450 transformations and affected by fewer significant interactions [<a href="#rid84">84,85</a>]. Hepatic uptake of rosuvastatin and pitavastatin is regulated by hepatocyte membrane transporters whose effect on statin concentrations can be altered by a smaller number of significant drug interactions.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CYP3A4 drugs</strong> – Drugs and substances that inhibit CYP3A4  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 2</a>) can increase the risk of statin myopathy due to <a class="drug drug_general" data-topicid="9575" href="/d/drug information/9575.html" rel="external">lovastatin</a>, <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a>, and to a lesser extent <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a> [<a href="#rid84">84</a>]. These include <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid25">25,86-89</a>], macrolide antibiotics (eg, <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a>) [<a href="#rid90">90</a>], systemic-azole antifungals [<a href="#rid91">91</a>], and HIV/hepatitis C virus (HCV) protease inhibitors including ritonavir-boosted regimens  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 2</a>) [<a href="#rid86">86,92-94</a>] and cobicistat-enhanced regimens [<a href="#rid94">94</a>]. Drugs that do not inhibit CYP3A4 but are competitive CYP3A4 substrates may also have myopathic interactions with statins, as has been reported with myotoxicity with simvastatin and atorvastatin and <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> and increased concentrations of simvastatin observed when taken with <a class="drug drug_general" data-topicid="8627" href="/d/drug information/8627.html" rel="external">amlodipine</a> [<a href="#rid34">34,95</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Calcium channel blockers </strong>– The non-dihydropyridine calcium channel blockers <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> and <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> are moderate inhibitors of CYP3A4 metabolism. Manufacturer data indicate that, at a <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a> dose of 20 to 80 mg/day, there is a 0.6 percent incidence of myopathy in patients also treated with verapamil (a value 10 times higher than seen in patients taking simvastatin without a calcium channel blocker) [<a href="#rid42">42</a>]. The risk is also increased when simvastatin is taken with <a class="drug drug_general" data-topicid="8627" href="/d/drug information/8627.html" rel="external">amlodipine</a>, which is metabolized by CYP3A4 [<a href="#rid73">73,96</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>HIV and HCV protease inhibitors</strong> – HIV protease inhibitors and pharmacologic boosters (eg, <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>, <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a>) and some HCV protease inhibitors (eg, <a class="drug drug_general" data-topicid="91660" href="/d/drug information/91660.html" rel="external">simeprevir</a>, paritaprevir) are potent inhibitors of CYP3A4. Thus, statins that are <strong>not </strong>highly dependent upon CYP3A4 for clearance (eg, <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">pravastatin</a>, <a class="drug drug_general" data-topicid="9532" href="/d/drug information/9532.html" rel="external">pitavastatin</a>) have been usual choices for patients receiving protease inhibitors who require statin treatment. When using statins that are metabolized by CYP3A4, low doses of <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a> and <a class="drug drug_general" data-topicid="10282" href="/d/drug information/10282.html" rel="external">rosuvastatin</a> are recommended. <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">Simvastatin</a> and <a class="drug drug_general" data-topicid="9575" href="/d/drug information/9575.html" rel="external">lovastatin</a> are contraindicated statins for patients treated with HIV protease inhibitors and cobicistat-containing coformulations. This practice is supported by manufacturer data and early case reports of myopathy and rhabdomyolysis in patients receiving lovastatin or simvastatin in combination with HIV protease inhibitors [<a href="#rid97">97</a>]. Of the newer statins, pitavastatin does not appear to interact with protease inhibitors, whereas rosuvastatin can interact with some HIV protease inhibitors by a non-CYP mechanism [<a href="#rid98">98-100</a>]. Between 2007 and 2015, cobicistat-containing antiretroviral regimens accounted for an increasing proportion of episodes of contraindicated statin use, based on analysis of pharmacy claims data [<a href="#rid94">94</a>]. Cobicistat interactions are common with atorvastatin, and the dosing of this agent should be restricted to 10 mg/day. Less important interactions in cobicistat-treated patients occur with rosuvastatin, which increases blood rosuvastatin levels by 18 percent [<a href="#rid101">101</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">Amiodarone</a> – Amiodarone and its metabolites can moderately inhibit CYP3A4 metabolism. Data from the manufacturer indicate that, at a <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a> dose of 80 mg/day, there is a 6 percent risk of myopathy in patients also treated with amiodarone [<a href="#rid42">42</a>]. The risk of rhabdomyolysis in patients treated concurrently with amiodarone appears to be higher with simvastatin than with other statins [<a href="#rid102">102</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Grapefruit juice</strong> – Grapefruit juice inhibits intestinal CYP3A4. However, daily consumption of up to 8 oz (240 mL) of grapefruit juice or one-half of a grapefruit, is unlikely to increase the risk of an adverse interaction or muscle injury [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">Cyclosporine</a> – Cyclosporine is an inhibitor of CYP3A4, CYP2C9, and the hepatocyte membrane efflux transporter organic anion transport protein (OATP), which regulates hepatic uptake of <a class="drug drug_general" data-topicid="8473" href="/d/drug information/8473.html" rel="external">fluvastatin</a>, <a class="drug drug_general" data-topicid="10282" href="/d/drug information/10282.html" rel="external">rosuvastatin</a>, and <a class="drug drug_general" data-topicid="9532" href="/d/drug information/9532.html" rel="external">pitavastatin</a>. Coadministration of cyclosporine can increase concentrations of fluvastatin twofold and rosuvastatin and pitavastatin by 3- to 10-fold or more [<a href="#rid99">99,104-106</a>]. Cyclosporine has been safely administered with fluvastatin doses of up to 40 mg/day [<a href="#rid107">107</a>]. Rosuvastatin and pitavastatin are dose-limited or contraindicated with cyclosporine, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fibrates</strong> – Fibrates are independently associated with muscle toxicity. An increased risk of muscle toxicity, as high as 1 to 5 percent, has been described with the administration of some statins (eg, <a class="drug drug_general" data-topicid="9575" href="/d/drug information/9575.html" rel="external">lovastatin</a>, <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a>, and <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a>) with <a class="drug drug_general" data-topicid="8488" href="/d/drug information/8488.html" rel="external">gemfibrozil</a> [<a href="#rid25">25,32,108,109</a>]. (See <a class="local">'Fibrates'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a> – Myopathy is an infrequent adverse effect of colchicine treatment and several cases have been reported following its coadministration with a statin, particularly in the setting of renal insufficiency. Multiple mechanisms seem to be involved as the interaction has been reported with a variety of statins, including <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">pravastatin</a> [<a href="#rid34">34,110</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8648" href="/d/drug information/8648.html" rel="external">Fusidic acid</a> – Several cases of rhabdomyolysis have been reported following coadministration of <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a> or <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a> with fusidic acid, an antimicrobial available primarily outside the United States [<a href="#rid111">111-117</a>]. The interaction appears to cause significant elevation in levels of both the statin and fusidic acid and could be due to inhibition of glucuronidation, but the exact mechanism is unknown.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9695" href="/d/drug information/9695.html" rel="external">Niacin</a> – Early reports suggested an increased risk of myopathy with combination niacin and statin treatment [<a href="#rid80">80</a>], and this is reflected in longstanding warnings found in some of the statin drug labels [<a href="#rid25">25,95</a>]. This complication appears to be uncommon, and the risk of myopathy has seemed similar to that of either agent taken separately [<a href="#rid81">81-83,118</a>]. However, in a large randomized trial in patients receiving <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a>, the combination of niacin and laropiprant increased the risk of definite myopathy (1.6 versus 0.4 events per 1000 patients per year; RR 4.4, 95% CI 2.6-7.5) [<a href="#rid74">74</a>]. The risk was particularly increased in participants from China (see <a class="local">'Patient characteristics'</a> above). It is uncertain whether niacin alone carries the same increased myopathy risk as niacin/laropiprant; however, this trial was much larger than prior studies and had the potential to have detected an interaction between niacin and statins that could have been missed in earlier smaller studies.</p><p></p><p>Management of these drug interactions, including choice of statin, dose limitations, and use of specific fibrates, is discussed below (see <a class="local">'Drug interactions'</a> below). For more detailed information about specific statin interactions, refer to the <a class="external" href="/drug-interactions">drug interaction program</a> included in UpToDate.</p><p class="headingAnchor" id="H107312769"><span class="h2">Exercise</span><span class="headingEndMark"> — </span>Studies offer conflicting results regarding the relationship between physical exercise and increases in muscle symptoms and CK elevations among statin users [<a href="#rid119">119-122</a>]. Exercise can induce rhabdomyolysis in patients with metabolic muscle disease, and vigorous unaccustomed exercise may be a risk factor for rhabdomyolysis in patients taking statins [<a href="#rid123">123</a>]. However, CK elevations and increases in muscle symptoms after exercise are typically mild and transient [<a href="#rid3">3</a>]. Such increases may not differ significantly between individuals with and without muscle-related symptoms prior to moderate-intensity exercise [<a href="#rid122">122</a>]. </p><p>The mechanism for muscle injury in statin-exposed patients is uncertain [<a href="#rid124">124</a>] but ultimately, as is the case with exercise-induced muscle injury in general, relates to repeated tensile forces incurred by the sarcolemma mediated via the cytoskeletal components such as the costameres and intermediate filaments [<a href="#rid125">125</a>].</p><p class="headingAnchor" id="H1207070513"><span class="h2">Combined risk factors</span><span class="headingEndMark"> — </span>In an analysis of three prospective trials (Heart Protection Study, Heart Protection Study-2, and SEARCH) involving 58,390 participants treated with <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a>, the effect of combined risk factors for simvastatin myopathy (defined as unexplained muscle pain or weakness with CK level &gt;10-fold above the upper limit of normal) was explored [<a href="#rid126">126</a>]. Individual risk factors included higher simvastatin dose, female sex, being Chinese (versus European), older age, lower body mass index, medically treated diabetes, and concomitant use of niacin-laropiprant, <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>, beta blockers, <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>, and diuretics. These risk factors were combined to form a weighted myopathy risk score, with a 30-fold difference in myopathy between the upper and lowest tertiles. The score was not associated with less severe myonecrosis (CK levels &lt;10-fold above the upper limit of normal). Prior research has indicated that many of these risk factors have a higher risk of SAMS [<a href="#rid4">4</a>]. Weakness of this analysis includes a definition of “myopathy” that is restricted to severe myonecrosis with symptoms, an analysis restricted to the use of simvastatin, and the lack of a systematic approach to the identification of reproducible muscle symptoms identified in randomized, placebo-controlled, crossover trials [<a href="#rid3">3,127</a>].</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Susceptible patients can have different constellations of statin-associated adverse muscle events (see <a class="local">'Definitions'</a> above), and these may not necessarily occur as a progression from less severe to more severe muscle injury in an individual patient  (<a class="graphic graphic_table graphicRef115539" href="/d/graphic/115539.html" rel="external">table 1</a> and <a class="graphic graphic_figure graphicRef115537" href="/d/graphic/115537.html" rel="external">figure 2</a>) [<a href="#rid3">3</a>]. Muscle events result from distinct pathophysiological entities that may overlap in certain patients. The most hazardous myopathic consequence is rhabdomyolysis, associated with acute renal failure [<a href="#rid86">86,128</a>]. (See  <a class="medical medical_review" href="/d/html/5169.html" rel="external">"Rhabdomyolysis: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H2293475482"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>Statin-induced myalgia and myopathy typically present as proximal, symmetric muscle weakness and/or soreness [<a href="#rid129">129</a>]. There may be muscle tenderness and there may be functional impairments such as difficulty raising the arms above the head, arising from a seated position, or climbing stairs; these symptoms are often described as fatigue or tiredness by the patient. Less often the discomfort is asymmetric. Other reported symptoms include cramping (including nocturnal cramping), stiffness [<a href="#rid38">38,130,131</a>], and tendon pain [<a href="#rid129">129</a>]. Some patients, but not all, have elevations in serum creatine kinase (CK). (See <a class="local">'Diagnosis'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h2">Time course of muscle events</span><span class="headingEndMark"> — </span>The onset of muscle symptoms is usually within weeks to months after the initiation of statin therapy but may occur at any time during treatment. As an example, a review of 44 cases of statin-associated myopathy found a mean duration of therapy before symptom onset of 6.3 months (range 0.25 to 48.0 months); approximately two-thirds of patients had onset of symptoms within six months of starting therapy [<a href="#rid132">132</a>].</p><p>Myalgias and weakness usually resolve and serum CK concentrations return to normal over days to weeks after discontinuation of the drug. In the above study, the mean time to resolution of symptoms in 43 patients who discontinued statin therapy was 2.3 months (range 0.25 to 14.0 months); 58 percent had resolution of symptoms within one month, and 93 percent had resolution within six months [<a href="#rid132">132</a>].</p><p class="headingAnchor" id="H639420584"><span class="h2">Exercise tolerance</span><span class="headingEndMark"> — </span>There have been concerns about the effects of statin therapy on exercise tolerance even in the absence of other symptoms; however, data are conflicting [<a href="#rid24">24,133</a>]. Further study is needed to clarify whether some or all statins have important effects on aerobic and muscle fitness in response to exercise.</p><p>In some circumstances, exercise may increase the risk for muscle injury in patients taking statins. (See <a class="local">'Exercise'</a> above.)</p><p class="headingAnchor" id="H639421012"><span class="h2">Neuromuscular disorders</span><span class="headingEndMark"> — </span>Statin therapy has been associated with a variety of neuromuscular disorders, including inflammatory myopathies such as polymyositis, dermatomyositis, and inclusion body myositis as well as immune-mediated necrotizing myopathy (IMNM) [<a href="#rid134">134-142</a>]. (See  <a class="medical medical_review" href="/d/html/14918.html" rel="external">"Pathogenesis of inflammatory myopathies"</a>.)</p><p>Statin-associated IMNM and inflammatory myopathy may represent a pathophysiological spectrum rather than categorical entities [<a href="#rid143">143</a>].</p><p>Although IMNM is rare, the clinician must always be aware of the possibility of its presence whenever statin-associated muscle symptoms (SAMS) fail to resolve several weeks after statin discontinuation, in which case referral to a muscle specialist is needed. Further, immediate referral is warranted if SAMS worsens after statins are discontinued. Patients typically have mild to moderate symmetric proximal muscle weakness. Rarely, mild joint pain or rash may be present [<a href="#rid6">6</a>]; the rash may affect the face, chest, or dorsal hand and therefore resemble dermatomyositis [<a href="#rid144">144</a>]. Necrotizing myopathies can be idiopathic, paraneoplastic, or associated with a connective-tissue disorder.</p><p>In necrotizing myopathy, scattered necrotic muscle fibers are present. This apparently histologically distinct noninflammatory statin myopathy is characterized by a macrophagocytic infiltrate engulfing necrotic muscle fibers, responds to immune therapy, and is presumably autoimmune [<a href="#rid142">142,145,146</a>]. Despite the lack of inflammation in the muscle itself, IMNM appears to be due to antibodies to hydroxymethylglutaryl (HMG)-CoA reductase (HMGCR) in regenerating muscle, and possibly other proteins [<a href="#rid145">145,147,148</a>]. In addition, intramuscular edema may be seen on magnetic resonance imaging (MRI) and inflammation of the surrounding fascia and subcutaneous tissue may be seen on biopsy [<a href="#rid148">148</a>]. (See  <a class="medical medical_review" href="/d/html/14918.html" rel="external">"Pathogenesis of inflammatory myopathies", section on 'Immune-mediated necrotizing myopathy'</a>.)</p><p>Other disorders that may have been induced by statin therapy include mononeuritis multiplex [<a href="#rid149">149</a>] and statin-induced extraocular muscle myopathy mimicking Graves' ophthalmopathy [<a href="#rid150">150</a>]. Additionally, patients who develop statin myopathy appear to be at increased risk for having malignant hyperthermia susceptibility [<a href="#rid151">151,152</a>]. (See  <a class="medical medical_review" href="/d/html/403.html" rel="external">"Susceptibility to malignant hyperthermia: Evaluation and management", section on 'Myopathies with ryanodine receptor abnormalities'</a>.)</p><p>Treatment is discussed below. (See <a class="local">'Immune-mediated necrotizing myopathy'</a> below.)</p><p class="headingAnchor" id="H107311578"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of symptomatic and more severe myositis and myonecrosis with laboratory abnormalities (ie, increased serum creatine kinase [CK]) is typically straightforward and based on a temporal association for both onset with initiation of statin therapy and resolution with statin withdrawal.</p><p>However, many patients can have muscle symptoms from statin therapy without an elevation in serum CK. This issue was directly addressed in a crossover study in which 4 of 21 blinded patients who had muscle symptoms while taking a statin (aching, weakness, decreased exercise tolerance) could distinguish statin therapy from placebo because of reproducible muscle symptoms [<a href="#rid52">52</a>]. Strength testing confirmed muscle weakness during statin therapy that resolved during placebo treatment; unblinded review of muscle biopsies showed evidence of mitochondrial dysfunction that also reversed with cessation of therapy. Serum statin concentrations were not inappropriately increased.</p><p>There are many other common causes of muscle pain and weakness, including overuse and other injuries, and pain syndromes such as fibromyalgia and myofascial pain syndrome. (See  <a class="medical medical_review" href="/d/html/7757.html" rel="external">"Overview of soft tissue musculoskeletal disorders"</a> and  <a class="medical medical_review" href="/d/html/5624.html" rel="external">"Clinical manifestations and diagnosis of fibromyalgia in adults"</a> and  <a class="medical medical_review" href="/d/html/5625.html" rel="external">"Differential diagnosis of fibromyalgia"</a> and  <a class="medical medical_review" href="/d/html/2751.html" rel="external">"Approach to the patient with myalgia"</a>.)</p><p>Distinguishing among these is typically based on a careful history and trials of cessation and reintroduction of statin therapy. Even with this, in some patients it will be difficult to be certain whether muscle symptoms are due to statin therapy, especially considering the variability in the timing of onset and offset of statin-associated muscle symptoms (SAMS) (see <a class="local">'Time course of muscle events'</a> above). A scoring system, the SAMS clinical index (SAMS-CI), was proposed for statin-associated symptoms [<a href="#rid3">3</a>] and later revised  (<a class="graphic graphic_figure graphicRef115537" href="/d/graphic/115537.html" rel="external">figure 2</a>) [<a href="#rid153">153</a>]. Validation of the scoring system showed that a low score &lt;5 had a negative predictive value of 91 percent in correctly excluding patients with true statin myalgia [<a href="#rid127">127</a>] but the scoring system has not been evaluated for clinical utility. A general approach to patients with myalgia is discussed separately. (See  <a class="medical medical_review" href="/d/html/2751.html" rel="external">"Approach to the patient with myalgia"</a>.)</p><p>The sensitivity and specificity of muscle biopsy for statin myopathy are unknown, and we do not typically use this test clinically, unless the muscle symptoms signs (eg, weakness, elevation of CK, etc) do not resolve upon statin discontinuation. Muscle biopsy obtained early in the course of rhabdomyolysis shows myonecrosis without vasculitis or significant inflammation. Biopsy later in the course may show some mononuclear cell infiltration suggestive of an inflammatory repair process [<a href="#rid30">30-32</a>].</p><p>Clinical judgment is necessary in interpreting increased CK levels in patients on statins. CK elevations can be related to hypothyroidism or muscle injury during sports (eg, running, hockey, impact or collision sports), and if a CK is to be measured in patients who engage in high-impact sports, it should be measured before engaging in exercise that day (see  <a class="medical medical_review" href="/d/html/5161.html" rel="external">"Muscle enzymes in the evaluation of neuromuscular diseases"</a>). In addition, there are differences in serum CK levels among racial groups  (<a class="graphic graphic_table graphicRef70806" href="/d/graphic/70806.html" rel="external">table 3</a>) [<a href="#rid154">154,155</a>].</p><p>Some patients report pain with statin therapy after having been warned about the potential side effect, without a pattern that suggests typical statin myalgias. In some of these patients, the statins may not actually be causing physiologic pain, but instead concerns about side effects may be heightening patient perception of pain from other causes.</p><p>A study used n-of-1 trials in eight patients who developed pain within three weeks of initiating statin therapy and who had no clinically significant elevation in CK, a measure of myonecrosis, to examine whether statins were actually the cause of the myalgias [<a href="#rid156">156</a>]. Seven patients underwent three pairs of treatments and one patient underwent two pairs of treatments, with each treatment pair consisting of three weeks of therapy with statin (at the dose that had been used clinically in that patient) or placebo, a three-week washout period, and the opposite therapy (placebo or statin). None of the eight patients had a statistically significant difference in pain scores between statin and placebo treatment periods. Five of the eight patients resumed and tolerated open-label statin therapy after learning the results of their n-of-1 trials.</p><p>It is uncertain whether these results would apply to typical patients seen outside of recruitment for a study and where the diagnosis of statin myopathy is in doubt. Additionally, the total number of patients in the study was small. Although an editorial comment that accompanied the article suggested that n-of-1 trials could be clinically useful, patients in most clinical settings do not have simple access to such trials.</p><p class="headingAnchor" id="H16"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>Despite the increased risk of myopathy associated with statin therapy, routine monitoring of serum creatine kinase (CK) levels is not recommended, based on a retrospective study of over 1000 patients in a primary care practice in which there were no significantly abnormal, and only two moderately abnormal, CK values potentially related to statin use [<a href="#rid29">29</a>]. However, it is useful to obtain a baseline serum CK before initiation of statin therapy for reference in case symptoms develop.</p><p>Patients treated with statins should be alerted to report the new onset of myalgias or weakness.</p><p class="headingAnchor" id="H301173463"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>No other treatment, aside from statin cessation, is necessary in most cases of statin-associated muscle symptoms (SAMS). Two notable exceptions are clinical rhabdomyolysis (urinary myoglobin with or without deterioration in kidney function), which always requires careful monitoring and supportive care, nearly always in an in-patient setting, and immune-mediated necrotizing myopathy, in which case immunosuppressive therapy is required. (See <a class="local">'Neuromuscular disorders'</a> above.)</p><p class="headingAnchor" id="H3941854172"><span class="h2">Rhabdomyolysis</span><span class="headingEndMark"> — </span>Patients with symptomatic or asymptomatic rhabdomyolysis from a statin should discontinue therapy immediately. Based on clinical experience, in the absence of clinical symptoms, a creatine kinase (CK) level &gt;10 times the upper limit of normal that is felt to be due to a statin is an indication for discontinuing the medication. Patients should drink large quantities of fluids to facilitate renal excretion of myoglobin and to help prevent renal failure.</p><p>Patients with a history of statin-induced rhabdomyolysis should generally not be treated with another statin because of the risk of recurrence [<a href="#rid123">123</a>]. In some cases, however, it may be reasonable to retry statin therapy after the resolution of an acute reversible event that contributed to muscle toxicity (eg, undetected hypothyroidism, acute renal failure, biliary obstruction, use of other medications that increase statin levels).</p><p>The clinical presentation, diagnosis, and management of rhabdomyolysis are discussed separately. (See  <a class="medical medical_review" href="/d/html/5169.html" rel="external">"Rhabdomyolysis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/14036.html" rel="external">"Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)"</a>.)</p><p class="headingAnchor" id="H664974600"><span class="h2">Immune-mediated necrotizing myopathy</span><span class="headingEndMark"> — </span>Management of this condition includes immediate statin discontinuation. In addition, treatment with oral steroid, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, intravenous immunoglobulin (<a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a>), and/or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> appears to be reasonable and safe, and these agents are commonly used. The severity of the weakness coupled with the CK elevation guides the selection and dosing of these potential agents. The European Neuromuscular Centre (ENMC) has produced a guidance document to assist the clinician in the treatment of these patients [<a href="#rid157">157,158</a>]. (See <a class="local">'Neuromuscular disorders'</a> above.)</p><p class="headingAnchor" id="H3321061399"><span class="h2">Other muscular toxicity</span></p><p class="headingAnchor" id="H4039438328"><span class="h3">General approach</span><span class="headingEndMark"> — </span>If a patient requires a statin and experiences muscle symptoms (other than rhabdomyolysis), we suggest the following approach:</p><p>Administer the SAMS clinical index (SAMS-CI)  (<a class="graphic graphic_figure graphicRef115537" href="/d/graphic/115537.html" rel="external">figure 2</a>) to determine the likelihood that muscle symptoms are due to statin use.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>For patients with a low SAMS-CI score (2 to 4):</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Discontinue the statin.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evaluate for other causes of symptoms, including depression and anxiety or medication-related side effects.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Wait for symptom resolution.</p><p></p><p class="bulletIndent1">After symptom resolution:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If patient was not on a high-intensity statin, restart the same statin at a lower dose.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If patient was on a high-intensity statin, switch to an alternative high-intensity statin (<a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a>, <a class="drug drug_general" data-topicid="10282" href="/d/drug information/10282.html" rel="external">rosuvastatin</a>) and address concerns about side effects. If the patient experiences adverse muscle symptoms on the alternative high-intensity statin, we recommend switching to <a class="drug drug_general" data-topicid="8473" href="/d/drug information/8473.html" rel="external">fluvastatin</a>, <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">pravastatin</a>, or <a class="drug drug_general" data-topicid="9532" href="/d/drug information/9532.html" rel="external">pitavastatin</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the patient was already on a low daily dose of a statin, consider alternate-day dosing [<a href="#rid4">4</a>]. (See <a class="local">'Alternate-day dosing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For patients with a high SAMS-CI score (5 to 11):</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Discontinue the statin.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Assess for drug interactions, including those related to addition of a new medication or a change in administration of a long-term medication that may account for symptoms.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Assess for comorbidities which may account for or exacerbate symptoms (vitamin D deficiency, hypothyroidism, acute or chronic renal failure, or obstructive liver disease). Correct hypothyroidism or low vitamin D level if present.</p><p></p><p class="bulletIndent1">After symptom resolution:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If patient was not on a high-intensity statin, restart the same statin at same or lower dose. If patient was already on the lowest dose, consider alternate-day dosing, although this may result in lower efficacy. (See <a class="local">'Alternate-day dosing'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If patient was on a high-intensity statin, switch to an alternative high-intensity statin (<a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a>, <a class="drug drug_general" data-topicid="10282" href="/d/drug information/10282.html" rel="external">rosuvastatin</a>) and address concerns about side effects. If the patient experiences adverse muscle symptoms on the alternative high-intensity statin, we recommend switching to <a class="drug drug_general" data-topicid="8473" href="/d/drug information/8473.html" rel="external">fluvastatin</a>, <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">pravastatin</a>, or <a class="drug drug_general" data-topicid="9532" href="/d/drug information/9532.html" rel="external">pitavastatin</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Readminister the SAMS-CI between 4 and 12 weeks.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the SAMS-CI score is still high, switch to a statin with different pharmacokinetic properties  (<a class="graphic graphic_table graphicRef53730" href="/d/graphic/53730.html" rel="external">table 4</a>) and/or consider non-statin low-density lipoprotein (LDL) cholesterol-lowering therapy.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If switching statin therapy to an agent with a different pharmacokinetic profile is unsuccessful [<a href="#rid153">153</a>], initiate alternate-day (or less frequent) dosing with careful monitoring. (See <a class="local">'Alternate-day dosing'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If SAMS-CI score is low, consider and evaluate for non-statin-associated conditions or therapies that may be causing symptoms.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If symptoms persist, discontinue all statin therapy and consider non-statin cholesterol-lowering therapy.</p><p></p><p class="headingAnchor" id="H1247186946"><span class="h3">Vitamin D</span><span class="headingEndMark"> — </span>If a patient with statin myopathy is known to be vitamin D deficient, it is reasonable to assess vitamin D status and, in patients with vitamin D deficiency, administer vitamin D replacement therapy and then rechallenge with statin therapy. Low vitamin D levels are associated with myopathy in statin-treated patients [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Summary and recommendations'</a>.)</p><p>Some studies, but not all, have suggested that low vitamin D levels may be associated with statin myopathy [<a href="#rid159">159</a>]. Case reports, case series, and some small, inadequately controlled studies have reported improvement in symptoms of statin myopathy in patients supplemented with vitamin D [<a href="#rid159">159,160</a>]. Although vitamin D deficiency might be a cause of statin myopathy, it may instead be a marker for other factors for myopathy (such as other nutritional deficiencies).</p><p class="headingAnchor" id="H301173471"><span class="h3">Switching statins</span><span class="headingEndMark"> — </span>As discussed above, <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">pravastatin</a>, <a class="drug drug_general" data-topicid="8473" href="/d/drug information/8473.html" rel="external">fluvastatin</a>, and <a class="drug drug_general" data-topicid="9532" href="/d/drug information/9532.html" rel="external">pitavastatin</a> appear to have much less intrinsic muscle toxicity than other statins (see <a class="local">'Statin characteristics'</a> above). Thus, in patients who have developed statin myopathy (other than rhabdomyolysis) on a statin other than pravastatin, pitavastatin, or fluvastatin, an option is to switch to one of those medications once symptoms have resolved off statin therapy.</p><p class="headingAnchor" id="H262665596"><span class="h3">Alternate-day dosing</span><span class="headingEndMark"> — </span>Daily dosing of statins is preferred whenever possible, since daily regimens are the ones that have been studied and proven to reduce clinical events. Clinical experience suggests that alternate-day dosing may improve the tolerability of statins in patients experiencing myalgias, and this strategy appears to have equal LDL cholesterol-lowering efficacy [<a href="#rid161">161</a>] and can reasonably be tried in patients unable to tolerate daily statin therapy.</p><p>However, it is possible that alternate-day dosing, especially of shorter-acting statins, may result in decreased efficacy. Alternate day-dosing presumes that LDL cholesterol levels are as well controlled between doses as when the statin is given daily. This may be the case with longer-acting statins (eg, <a class="drug drug_general" data-topicid="10282" href="/d/drug information/10282.html" rel="external">rosuvastatin</a>, <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a>) but is less likely with shorter-acting statins (eg, <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a>, <a class="drug drug_general" data-topicid="8473" href="/d/drug information/8473.html" rel="external">fluvastatin</a>, <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">pravastatin</a>, <a class="drug drug_general" data-topicid="9575" href="/d/drug information/9575.html" rel="external">lovastatin</a>) whose half-lives are less than six hours. We prefer to use alternate-day dosing only with long-acting statins. However, if alternate-day dosing with a shorter acting statin is chosen, we would measure the LDL cholesterol at the nadir of the dosing regimen to ensure adequate lowering of the LDL cholesterol level. We do not use regimens that extend the dosing interval beyond every other day, such as once-weekly regimens, as these are very unlikely to control LDL cholesterol levels adequately. (See  <a class="medical medical_review" href="/d/html/4564.html" rel="external">"Statins: Actions, side effects, and administration", section on 'Alternative dosing regimens'</a>.)</p><p class="headingAnchor" id="H2175839177"><span class="h3">Therapies of uncertain benefit</span></p><p class="headingAnchor" id="H639421405"><span class="h4">Coenzyme Q10</span><span class="headingEndMark"> — </span>We suggest not administering Coenzyme Q10 (CoQ10) to try to improve or prevent statin-associated muscle events. As discussed above, CoQ10 depletion that reduces skeletal muscle ubiquinone concentrations may play a role in statin myopathy (see <a class="local">'Pathogenesis'</a> above). However, there is little published evidence showing benefit of CoQ10 supplements for the treatment of myalgia or myopathy [<a href="#rid3">3</a>].</p><p>The American Heart Association (AHA) statement on statin safety concluded that CoQ10 is not helpful in SAMS [<a href="#rid162">162</a>].</p><p>In our view, the best available evidence is from a small randomized double-blind, placebo, crossover trial that found no benefit of CoQ10 at a dose of 600 mg/day in patients with simvastatin-induced myalgia [<a href="#rid163">163</a>]. In this trial, participants were tested prior to enrollment for the presence of a true statin myalgia by being randomized to <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a> or placebo for eight weeks and then crossed over to the other therapy. Symptoms were measured in each phase, and only 35.8 percent of participants were categorized as having true statin myalgia (ie, symptoms on the statin but not on the placebo) and allowed to continue in the trial. Among the other participants, 29.2 percent experienced symptoms on placebo but not on simvastatin, and 17.5 percent experienced pain on both simvastatin and placebo. These results highlight the fact that many patients are likely to have symptoms that are not a true statin myalgia, and this information diminishes our confidence in the patient selection for other trials without this pre-testing.</p><p>In a meta-analysis of 12 placebo-controlled randomized trials (n = 575 patients) assessing the effects of CoQ10 supplementation on SAMS and plasma CK, CoQ10 supplementation ameliorated SAMS such as [<a href="#rid164">164</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Muscle pain (weighted mean difference [WMD] -1.60, 95% CI -1.75 to -1.44)</p><p class="bulletIndent1"><span class="glyph">●</span>Muscle weakness (WMD -2.28, 95% CI -2.79 to -1.77)</p><p class="bulletIndent1"><span class="glyph">●</span>Muscle cramp (WMD -1.78, 95% CI -2.31 to -1.24)</p><p class="bulletIndent1"><span class="glyph">●</span>Muscle tiredness (WMD -1.75, 95% CI -2.31 to -1.19)</p><p></p><p>There was no meaningful difference in the plasma CK levels. Although symptoms were reduced, there was substantial heterogeneity among trials, and most did not attempt to identify patients with true statin myalgia.</p><p>The evidence for CoQ10 for prevention of muscle events is even more limited. (See <a class="local">'Use of coenzyme Q10 for prevention'</a> below.)</p><p class="headingAnchor" id="H583893250"><span class="h4">Red yeast rice</span><span class="headingEndMark"> — </span>Red yeast rice (<em>Monascus purpureus</em>) is a nutraceutical that lowers LDL cholesterol levels by 20 to 30 percent. The LDL cholesterol-lowering effect of red yeast rice is due to the presence of monacolin K, a compound similar to <a class="drug drug_general" data-topicid="9575" href="/d/drug information/9575.html" rel="external">lovastatin</a>. Although red yeast rice lowers LDL cholesterol similar to a low-efficacy statin and may be tolerated by some patients who have discontinued statin therapy for muscle side effects, this therapy is not recommended due to lack of clinical outcomes data, variable drug bioavailability [<a href="#rid165">165</a>], and possible toxic effects from contaminants. Red yeast rice may also induce muscle complaints because of its statin-like content [<a href="#rid166">166-168</a>]. (See  <a class="medical medical_review" href="/d/html/4561.html" rel="external">"Lipid management with diet or dietary supplements"</a>.)</p><p class="headingAnchor" id="H301173455"><span class="h1">PREVENTION</span></p><p class="headingAnchor" id="H301173654"><span class="h2">Choice of statin</span><span class="headingEndMark"> — </span>As discussed above, <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">pravastatin</a>, <a class="drug drug_general" data-topicid="8473" href="/d/drug information/8473.html" rel="external">fluvastatin</a>, and <a class="drug drug_general" data-topicid="9532" href="/d/drug information/9532.html" rel="external">pitavastatin</a> appear to have much less intrinsic muscle toxicity than other statins (see <a class="local">'Statin characteristics'</a> above). All of these agents are relatively lower efficacy statins; however, whenever they are adequate for the clinical situation, we suggest treating with one or the other to reduce the risk of statin myopathy.</p><p>As discussed below, the choice of statin is also important in dealing with potential drug interactions. (See <a class="local">'Drug interactions'</a> below.)</p><p class="headingAnchor" id="H301173662"><span class="h2">Drug interactions</span><span class="headingEndMark"> — </span>Certain drug interactions are discussed below. Additional detail about specific statin interactions and management suggestions for avoiding increased myopathy risk is available by using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p class="headingAnchor" id="H301173724"><span class="h3">CYP3A4 drugs</span><span class="headingEndMark"> — </span>As discussed above, the risk of muscle injury is substantially increased when taking the combination of statins extensively metabolized by cytochrome P450 3A4 (CYP3A4; <a class="drug drug_general" data-topicid="9575" href="/d/drug information/9575.html" rel="external">lovastatin</a>, <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a>, <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a>) and drugs that inhibit CYP3A4  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 2</a>) (see <a class="local">'Concurrent drug therapy'</a> above). <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">Pravastatin</a>, <a class="drug drug_general" data-topicid="8473" href="/d/drug information/8473.html" rel="external">fluvastatin</a>, and <a class="drug drug_general" data-topicid="9532" href="/d/drug information/9532.html" rel="external">pitavastatin</a> are preferred when concurrent therapy with a strong inhibitor of CYP3A4 cannot be avoided.</p><p>The importance of using a statin that is not extensively metabolized by CYP3A4 when administering a CYP3A4 inhibitor is illustrated by the moderate CYP3A4 inhibitor <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>. Regular-dose <a class="drug drug_general" data-topicid="9575" href="/d/drug information/9575.html" rel="external">lovastatin</a> (40 to 80 mg/day) and <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a> (20 mg/day) are associated with an appreciable risk of myositis (as high as 13 to 30 percent) in cyclosporine-treated patients [<a href="#rid25">25,86,87</a>]. Lovastatin levels much higher than the therapeutic range have been noted in patients with rhabdomyolysis who were treated with cyclosporine [<a href="#rid25">25</a>]. Although the data are limited, myositis has also been described when cyclosporine is given with <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a>, which is metabolized by CYP3A4 [<a href="#rid88">88,89</a>]. By contrast, <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">pravastatin</a> and <a class="drug drug_general" data-topicid="8473" href="/d/drug information/8473.html" rel="external">fluvastatin</a>, which are not extensively metabolized by CYP3A4, do not appear to increase the risk of myopathy when given concurrently with cyclosporine [<a href="#rid87">87,169-171</a>].</p><p>The safety of <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">pravastatin</a> in such patients was illustrated in an open-label study that compared pravastatin (40 mg/day) with <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a> (20 mg/day) in 87 cardiac transplant recipients [<a href="#rid87">87</a>]. Rhabdomyolysis or myositis occurred only with simvastatin therapy (13.3 percent). A similar lack of muscle toxicity was noted in a placebo-controlled trial in which none of 50 cardiac transplant recipients treated with pravastatin (40 mg/day) developed myalgia or myositis during one year of therapy [<a href="#rid169">169</a>].</p><p>The safety of <a class="drug drug_general" data-topicid="8473" href="/d/drug information/8473.html" rel="external">fluvastatin</a> (20 and 40 mg/day) taken with <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> in hypercholesterolemic renal transplant patients has been demonstrated in several small trials in which mean serum trough levels of cyclosporine were not significantly altered [<a href="#rid107">107,172,173</a>].</p><p>Although <a class="drug drug_general" data-topicid="9532" href="/d/drug information/9532.html" rel="external">pitavastatin</a> and <a class="drug drug_general" data-topicid="10282" href="/d/drug information/10282.html" rel="external">rosuvastatin</a> are not significantly metabolized by CYP3A4, manufacturers' pharmacokinetic data show they can interact with <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, apparently by a non-CYP mechanism [<a href="#rid99">99,106</a>]. Hepatic uptake of pitavastatin and rosuvastatin is regulated by hepatocyte membrane transporters, known as organic anion transport proteins (OATPs), whose effects can be inhibited by certain drugs (ie, cyclosporine, <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a>, <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>), causing increased levels of pitavastatin or rosuvastatin [<a href="#rid174">174,175</a>]; there is some evidence that clarithromycin can increase the risk of rhabdomyolysis even in patients taking statins that are not metabolized by CYP3A4 [<a href="#rid176">176</a>].</p><p class="headingAnchor" id="H301173732"><span class="h3">Fibrates</span><span class="headingEndMark"> — </span>The concomitant use of fibrates and statins can increase the risk of muscle injury, including rhabdomyolysis [<a href="#rid2">2</a>]. The effect is due to an increase in statin levels and varies according to the fibrate and statin. Toxicity can be minimized by the choice of fibrate and by using statins at relatively low doses [<a href="#rid177">177-179</a>]. The lowest risk is with the use of <a class="drug drug_general" data-topicid="91482" href="/d/drug information/91482.html" rel="external">fenofibrate</a> and either <a class="drug drug_general" data-topicid="8473" href="/d/drug information/8473.html" rel="external">fluvastatin</a>, <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">pravastatin</a>, or <a class="drug drug_general" data-topicid="9532" href="/d/drug information/9532.html" rel="external">pitavastatin</a> at the lowest effective dose.</p><p><a class="drug drug_general" data-topicid="91482" href="/d/drug information/91482.html" rel="external">Fenofibrate</a> is the preferred fibrate in patients who require combined therapy with a statin due to minimal risk of increase in statin levels [<a href="#rid180">180</a>]. It appears to be safer than <a class="drug drug_general" data-topicid="8488" href="/d/drug information/8488.html" rel="external">gemfibrozil</a> due to a differential effect on statin excretion [<a href="#rid181">181,182</a>].</p><p>The relative safety of <a class="drug drug_general" data-topicid="91482" href="/d/drug information/91482.html" rel="external">fenofibrate</a> has been demonstrated in meta-analyses and individual trials, in which there has been no increase in muscle-related adverse events in patients taking fenofibrate plus a statin compared with a statin alone [<a href="#rid183">183-185</a>].</p><p><a class="drug drug_general" data-topicid="8488" href="/d/drug information/8488.html" rel="external">Gemfibrozil</a> has a greater potential to increase plasma levels of statins and risk for muscle toxicity, especially when used with <a class="drug drug_general" data-topicid="9575" href="/d/drug information/9575.html" rel="external">lovastatin</a>, <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a>, or <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a> [<a href="#rid25">25,32,108,109</a>]. <a class="drug drug_general" data-topicid="8473" href="/d/drug information/8473.html" rel="external">Fluvastatin</a> and <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">pravastatin</a> are the safest statins in this situation [<a href="#rid177">177,186-191</a>] and can be considered for use with gemfibrozil if the benefit is likely to outweigh the risk.</p><p class="headingAnchor" id="H7754121"><span class="h3">Niacin</span><span class="headingEndMark"> — </span>Although the overall increase in risk of statin-associated muscle symptoms (SAMS) with concurrent use of <a class="drug drug_general" data-topicid="9695" href="/d/drug information/9695.html" rel="external">niacin</a> with statins appears to be small, niacin seems to increase the risk of myopathy in patients receiving <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a> and perhaps other statins (see <a class="local">'Concurrent drug therapy'</a> above). This increased risk may be a particular concern in patients from China (see <a class="local">'Patient characteristics'</a> above), and we suggest avoiding the combination of simvastatin and niacin in Chinese patients and only using niacin with caution in patients receiving other statins.</p><p class="headingAnchor" id="H301173755"><span class="h3">Dose limitations</span><span class="headingEndMark"> — </span>Manufacturer recommendations for <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a>, and also for <a class="drug drug_general" data-topicid="9575" href="/d/drug information/9575.html" rel="external">lovastatin</a>, state that the medications are contraindicated in patients treated with most strong CYP3A4 inhibitors  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 2</a>) and that there are dose limitations or recommendations to avoid these statins when used in conjunction with a number of other medications, including limiting simvastatin to 20 mg/day when taken with <a class="drug drug_general" data-topicid="8627" href="/d/drug information/8627.html" rel="external">amlodipine</a> [<a href="#rid73">73,96</a>].</p><p>Given high rates of myopathy with <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a> 80 mg/day [<a href="#rid192">192</a>] and the availability of <a class="drug drug_general" data-topicid="10282" href="/d/drug information/10282.html" rel="external">rosuvastatin</a> and generic <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a>, we suggest not treating patients with doses of simvastatin above 40 mg/day. Additionally, clinicians should strongly consider switching even patients who are currently tolerating simvastatin 80 mg/day to one of these other statin options. (See  <a class="medical medical_review" href="/d/html/4564.html" rel="external">"Statins: Actions, side effects, and administration", section on 'Potency'</a>.)</p><p>For more detailed information about dose limitations, refer to the individual drug monographs included with UpToDate.</p><p class="headingAnchor" id="H301173647"><span class="h2">Use of coenzyme Q10 for prevention</span><span class="headingEndMark"> — </span>Some clinicians recommend that patients taking statins take Coenzyme Q10 (CoQ10) to try to prevent myopathy, and a few case reports have noted benefit with doses of 30 to 250 mg/day [<a href="#rid193">193</a>]. Further, a meta-analysis of several small clinical trials suggests benefit [<a href="#rid164">164</a>]. Nonetheless, we feel that there is inadequate evidence to recommend CoQ10 supplementation for prevention of statin-induced muscle toxicity based on a randomized, double-blind placebo-controlled crossover trial [<a href="#rid194">194</a>].</p><p class="headingAnchor" id="H2070152727"><span class="h2">Exercise</span></p><p class="headingAnchor" id="H1472091996"><span class="h3">Approach to exercise for patients on statins</span><span class="headingEndMark"> — </span>Although exercise may trigger SAMS and increases in CK levels [<a href="#rid130">130</a>], patients who are taking statins should not avoid exercise. Statin-related injury from exercise is typically mild and subclinical [<a href="#rid3">3</a>]. Moreover, a graduated exercise program may mitigate the risk of muscle injury from unaccustomed vigorous exercise. </p><p class="headingAnchor" id="H2871637424"><span class="h3">Rationale for graduated physical training</span><span class="headingEndMark"> — </span>Graduated physical training may protect skeletal muscles from exercise-induced muscle injury. Graduated physical training induces mitochondrial biogenesis and upregulates antioxidant defense mechanisms. This may increase the oxidative capacity of skeletal muscles and thereby protect skeletal muscle fibers from the pro-oxidant effects of statins [<a href="#rid195">195</a>].</p><p class="headingAnchor" id="H170224670"><span class="h3">Holding statin prior to intensive exercise is usually not necessary</span><span class="headingEndMark"> — </span>In individuals who have done endurance training, statins can potentiate muscle injury from prolonged vigorous exercise. For example, one study showed greater increases in post-marathon CK levels in individuals receiving statins, and older runners receiving statins exhibited more susceptibility than younger runners [<a href="#rid196">196</a>]. Nonetheless, CK elevations were mild and subclinical, which suggests that most trained individuals need not discontinue statin therapy prior to a race.</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Statin muscle-related adverse events are relatively uncommon. Myalgias and myopathy occur with a frequency of 2 to 11 percent. However, severe myonecrosis and clinical rhabdomyolysis are much rarer (0.5 percent and less than 0.1 percent, respectively). Patients can experience statin-induced myalgias without an elevation in serum creatine kinase (CK) concentration. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Several risk factors have been identified, including the following (see <a class="local">'Risk factors'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choice of statin</strong> – The risk of muscle injury is substantially higher when taking a statin that is extensively metabolized by cytochrome P450 3A4 (CYP3A4; <a class="drug drug_general" data-topicid="9575" href="/d/drug information/9575.html" rel="external">lovastatin</a>, <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a>, <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a>) together with a drug that interferes with CYP3A4  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 2</a>). <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">Pravastatin</a>, <a class="drug drug_general" data-topicid="8473" href="/d/drug information/8473.html" rel="external">fluvastatin</a>, <a class="drug drug_general" data-topicid="10282" href="/d/drug information/10282.html" rel="external">rosuvastatin</a>, and <a class="drug drug_general" data-topicid="9532" href="/d/drug information/9532.html" rel="external">pitavastatin</a> are preferred when given to a patient receiving another drug that is a strong inhibitor of CYP3A4. (See <a class="local">'CYP3A4 drugs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patient characteristics</strong> – Enhanced susceptibility to statin-associated myopathy occurs in patients with neuromuscular disorders, acute or chronic renal failure, obstructive liver disease, and hypothyroidism. (See <a class="local">'Patient characteristics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Concurrent drug therapy</strong> – The increase in susceptibility to myopathy is substantially greater in patients receiving concurrent therapy with a number of drugs, particularly those that inhibit CYP3A4  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 2</a>). (See <a class="local">'Concurrent drug therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Muscle symptoms and/or signs usually begin within weeks to months after starting statins. Myalgias, weakness, and serum CK concentrations usually return to normal over days to weeks after drug discontinuation, although in a few cases they may require months to resolve. (See <a class="local">'Time course of muscle events'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of symptomatic statin myopathy with laboratory abnormalities (ie, increased serum CK) is typically straightforward and based on a temporal association for both onset with initiation of statin therapy and resolution with statin withdrawal. However, some patients can have muscle symptoms from statin therapy without an elevation in serum CK, and it can then be difficult to be certain whether muscle symptoms are due to statin therapy. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical judgment is necessary in interpreting increased CK levels in patients on statins. CK elevations can be related to hypothyroidism or muscle injury during sports (eg, running, diving for a volleyball, hockey), and patients who engage in high-impact sports should be advised to have any CK measurements done before engaging in exercise that day. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – In patients who develop evidence of muscle toxicity while on statin therapy, we use the statin-associated muscle symptoms clinical index (SAMS-CI) to determine the likelihood of statin involvement. We assess for drug interactions and check a vitamin D level and thyroid function. We use a step-wise approach to decisions regarding continuing, switching, or discontinuing statin therapy. (See <a class="local">'Concurrent drug therapy'</a> above and <a class="local">'Hypothyroidism, hypovitaminosis D, and other disorders'</a> above and <a class="local">'Vitamin D'</a> above and <a class="local">'General approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limited role for lab monitoring</strong> – We suggest <strong>not</strong> routinely monitoring serum CK levels in patients on statin therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). It is useful to obtain a baseline CK level for reference purposes prior to starting statin therapy. Patients treated with statins should be alerted to report the new onset of myalgias or weakness. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rhabdomyolysis</strong> – Patients with symptomatic or asymptomatic rhabdomyolysis from a statin should discontinue therapy immediately. (See <a class="local">'Rhabdomyolysis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immune-mediated necrotizing myopathy</strong> – Management of this condition includes immediate statin discontinuation. (See <a class="local">'Immune-mediated necrotizing myopathy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Switching statins</strong> – <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">Pravastatin</a>, <a class="drug drug_general" data-topicid="9532" href="/d/drug information/9532.html" rel="external">pitavastatin</a>, and <a class="drug drug_general" data-topicid="8473" href="/d/drug information/8473.html" rel="external">fluvastatin</a> appear to have much less associated muscle toxicity than other statins. Thus, in patients who have developed statin myopathy (other than rhabdomyolysis) on a statin other than pravastatin, pitavastatin, or fluvastatin, we suggest switching to one of these medications once symptoms have resolved off statin therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Switching statins'</a> above and <a class="local">'Statin characteristics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alternate-day dosing</strong> – In patients who are unable to tolerate daily dosing of <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">pravastatin</a>, <a class="drug drug_general" data-topicid="8473" href="/d/drug information/8473.html" rel="external">fluvastatin</a>, or <a class="drug drug_general" data-topicid="9532" href="/d/drug information/9532.html" rel="external">pitavastatin</a>, we suggest a trial of alternate-day or less frequent dosing (one to two times weekly) of statin therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Alternate-day dosing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Limited role for coenzyme Q10</strong> – We suggest <strong>not</strong> administering coenzyme Q10 (CoQ10) for treatment or prevention of statin myopathy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, there may be a subset of patients who may derive benefit, and there is little to no risk of harm in use of this nutraceutical. (See <a class="local">'Coenzyme Q10'</a> above and <a class="local">'Use of coenzyme Q10 for prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – Strategies for prevention include choice of statin and management of existing or potential drug interactions. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fibrates</strong> – In patients who require combined therapy with a fibrate and a statin (including <a class="drug drug_general" data-topicid="9804" href="/d/drug information/9804.html" rel="external">pravastatin</a> or <a class="drug drug_general" data-topicid="8473" href="/d/drug information/8473.html" rel="external">fluvastatin</a>), we suggest <a class="drug drug_general" data-topicid="91482" href="/d/drug information/91482.html" rel="external">fenofibrate</a> rather than <a class="drug drug_general" data-topicid="8488" href="/d/drug information/8488.html" rel="external">gemfibrozil</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Fibrates'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Grundy SM. Can statins cause chronic low-grade myopathy? Ann Intern Med 2002; 137:617.</a></li><li><a class="nounderline abstract_t">Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292:2585.</a></li><li><a class="nounderline abstract_t">Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 2014; 8:S58.</a></li><li><a class="nounderline abstract_t">Rosenson RS, Baker S, Banach M, et al. Optimizing Cholesterol Treatment in Patients With Muscle Complaints. J Am Coll Cardiol 2017; 70:1290.</a></li><li><a class="nounderline abstract_t">Brunham LR, Baker S, Mammen A, et al. Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. Cardiovasc Res 2018; 114:1073.</a></li><li><a class="nounderline abstract_t">Mammen AL. Statin-Associated Autoimmune Myopathy. N Engl J Med 2016; 374:664.</a></li><li><a class="nounderline abstract_t">Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993; 33:226.</a></li><li><a class="nounderline abstract_t">Rundek T, Naini A, Sacco R, et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol 2004; 61:889.</a></li><li><a class="nounderline abstract_t">Päivä H, Thelen KM, Van Coster R, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005; 78:60.</a></li><li><a class="nounderline abstract_t">Banach M, Serban C, Ursoniu S, et al. Statin therapy and plasma coenzyme Q10 concentrations--A systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res 2015; 99:329.</a></li><li><a class="nounderline abstract_t">Bleske BE, Willis RA, Anthony M, et al. The effect of pravastatin and atorvastatin on coenzyme Q10. Am Heart J 2001; 142:E2.</a></li><li><a class="nounderline abstract_t">Laaksonen R, Jokelainen K, Laakso J, et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996; 77:851.</a></li><li><a class="nounderline abstract_t">Lamperti C, Naini AB, Lucchini V, et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 2005; 62:1709.</a></li><li><a class="nounderline abstract_t">Larsen S, Stride N, Hey-Mogensen M, et al. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. J Am Coll Cardiol 2013; 61:44.</a></li><li><a class="nounderline abstract_t">Phillips PS, Ciaraldi TP, Kim DL, et al. Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids. Endocrine 2009; 35:38.</a></li><li><a class="nounderline abstract_t">Iacobazzi V, Convertini P, Infantino V, et al. Statins, fibrates and retinoic acid upregulate mitochondrial acylcarnitine carrier gene expression. Biochem Biophys Res Commun 2009; 388:643.</a></li><li><a class="nounderline abstract_t">Hanai J, Cao P, Tanksale P, et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 2007; 117:3940.</a></li><li><a class="nounderline abstract_t">Elam MB, Majumdar G, Mozhui K, et al. Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge. PLoS One 2017; 12:e0181308.</a></li><li><a class="nounderline abstract_t">Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36:1012.</a></li><li><a class="nounderline abstract_t">Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289:1681.</a></li><li><a class="nounderline abstract_t">Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J 2014; 168:6.</a></li><li><a class="nounderline abstract_t">Cholesterol Treatment Trialists' Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet 2022; 400:832.</a></li><li><a class="nounderline abstract_t">Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009; 150:858.</a></li><li><a class="nounderline abstract_t">Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation 2013; 127:96.</a></li><li><a class="nounderline abstract_t">Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62:28J.</a></li><li><a class="nounderline abstract_t">Dujovne CA, Chremos AN, Pool JL, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. Am J Med 1991; 91:25S.</a></li><li><a class="nounderline abstract_t">Boccuzzi SJ, Bocanegra TS, Walker JF, et al. Long-term safety and efficacy profile of simvastatin. Am J Cardiol 1991; 68:1127.</a></li><li><a class="nounderline abstract_t">Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996; 156:2085.</a></li><li><a class="nounderline abstract_t">Smith CC, Bernstein LI, Davis RB, et al. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med 2003; 163:688.</a></li><li><a class="nounderline abstract_t">Norman DJ, Illingworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl J Med 1988; 318:46.</a></li><li><a class="nounderline abstract_t">East C, Alivizatos PA, Grundy SM, et al. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988; 318:47.</a></li><li><a class="nounderline abstract_t">Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264:71.</a></li><li><a class="nounderline abstract_t">Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163:553.</a></li><li><a class="nounderline abstract_t">Baker SK, Goodwin S, Sur M, Tarnopolsky MA. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve 2004; 30:799.</a></li><li><a class="nounderline abstract_t">Mefford MT, Tajeu GS, Tanner RM, et al. Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in Stroke Study). Am J Cardiol 2018; 122:768.</a></li><li><a class="nounderline abstract_t">Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 2012; 6:208.</a></li><li><a class="nounderline abstract_t">Ito MK, Maki KC, Brinton EA, et al. Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study. J Clin Lipidol 2014; 8:69.</a></li><li><a class="nounderline abstract_t">Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther 2005; 19:403.</a></li><li><a class="nounderline abstract_t">Catapano AL. Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin. Curr Vasc Pharmacol 2012; 10:257.</a></li><li><a class="nounderline abstract_t">Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2016; 134:e468.</a></li><li><a class="nounderline abstract_t">Barilla D, Prasad P, Hubert M, Gumbhir-Shah K. Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL. Biopharm Drug Dispos 2004; 25:51.</a></li><li><a class="nounderline abstract_t">"The Pink Sheet" FDC Reports. 2002; 64(vol 23):5.</a></li><li><a class="nounderline abstract_t">Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002; 105:2341.</a></li><li><a class="nounderline abstract_t">Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195.</a></li><li><a class="nounderline abstract_t">"The Pink Sheet" FDC Reports. Chevy Chase, MD. 2004; 66:31.</a></li><li><a class="nounderline abstract_t">Zinman L, Sadeghi R, Gawel M, et al. Are statin medications safe in patients with ALS? Amyotroph Lateral Scler 2008; 9:223.</a></li><li><a class="nounderline abstract_t">Dupuis L, Corcia P, Fergani A, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 2008; 70:1004.</a></li><li><a class="nounderline abstract_t">Dupuis L, Oudart H, René F, et al. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci U S A 2004; 101:11159.</a></li><li><a class="nounderline abstract_t">Robichon C, Dugail I. De novo cholesterol synthesis at the crossroads of adaptive response to extracellular stress through SREBP. Biochimie 2007; 89:260.</a></li><li><a class="nounderline abstract_t">Parmar B, Francis PJ, Ragge NK. Statins, fibrates, and ocular myasthenia. Lancet 2002; 360:717.</a></li><li><a class="nounderline abstract_t">Cartwright MS, Jeffery DR, Nuss GR, Donofrio PD. Statin-associated exacerbation of myasthenia gravis. Neurology 2004; 63:2188.</a></li><li><a class="nounderline abstract_t">Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 137:581.</a></li><li><a class="nounderline abstract_t">Chariot P, Abadia R, Agnus D, et al. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med 1993; 94:109.</a></li><li><a class="nounderline abstract_t">Tsivgoulis G, Spengos K, Karandreas N, et al. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med 2006; 166:1519.</a></li><li><a class="nounderline abstract_t">Livingstone C, Al Riyami S, Wilkins P, Ferns GA. McArdle's disease diagnosed following statin-induced myositis. Ann Clin Biochem 2004; 41:338.</a></li><li><a class="nounderline abstract_t">Baker SK, Vladutiu GD, Tarnopolsky MA. McArdle disease unmasked by statin exposure. Muscle Nerve 2003; (Suppl 12):S73.</a></li><li><a class="nounderline abstract_t">Voermans NC, Lammens M, Wevers RA, et al. Statin-disclosed acid maltase deficiency. J Intern Med 2005; 258:196.</a></li><li><a class="nounderline abstract_t">Echaniz-Laguna A, Mohr M, Tranchant C. Neuromuscular symptoms and elevated creatine kinase after statin withdrawal. N Engl J Med 2010; 362:564.</a></li><li><a class="nounderline abstract_t">Delgado-López F, Bautista-Lorite J, Villamil-Fernández F. [Worsening for using statin in carnitine palmityol transferase deficiency myopathy]. Rev Neurol 2004; 38:1095.</a></li><li><a class="nounderline abstract_t">Baker SK, Tarnopolsky MA. Sporadic rippling muscle disease unmasked by simvastatin. Muscle Nerve 2006; 34:478.</a></li><li><a class="nounderline abstract_t">Knoblauch H, Schoewel V, Kress W, et al. Another side to statin-related side effects. Ann Intern Med 2010; 152:478.</a></li><li><a class="nounderline abstract_t">Supala-Berger A, Fine E, Heffner R, Young-McLain E. Hyaline inclusion myopathy: unmasked by statin therapy. Muscle Nerve 2009; 40:657.</a></li><li><a class="nounderline abstract_t">Evangelista T, Ferro J, Pereira P, de Carvalho M. A case of asymptomatic cytoplasmic body myopathy revealed by sinvastatin. Neuromuscul Disord 2009; 19:66.</a></li><li><a class="nounderline abstract_t">al-Jubouri MA, Briston PG, Sinclair D, et al. Myxoedema revealed by simvastatin induced myopathy. BMJ 1994; 308:588.</a></li><li><a class="nounderline abstract_t">Scalvini T, Marocolo D, Cerudelli B, et al. Pravastatin-associated myopathy. Report of a case. Recenti Prog Med 1995; 86:198.</a></li><li><a class="nounderline abstract_t">Kang JH, Nguyen QN, Mutka J, Le QA. Rechallenging Statin Therapy in Veterans With Statin-Induced Myopathy Post Vitamin D Replenishment. J Pharm Pract 2017; 30:521.</a></li><li><a class="nounderline abstract_t">Khayznikov M, Hemachrandra K, Pandit R, et al. Statin Intolerance Because of Myalgia, Myositis, Myopathy, or Myonecrosis Can in Most Cases be Safely Resolved by Vitamin D Supplementation. N Am J Med Sci 2015; 7:86.</a></li><li><a class="nounderline abstract_t">Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol 2015; 178:111.</a></li><li><a class="nounderline abstract_t">Vladutiu GD. Genetic predisposition to statin myopathy. Curr Opin Rheumatol 2008; 20:648.</a></li><li><a class="nounderline abstract_t">SEARCH Collaborative Group, Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med 2008; 359:789.</a></li><li><a class="nounderline abstract_t">Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009; 54:1609.</a></li><li><a class="nounderline abstract_t">Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res 2010; 106:297.</a></li><li class="breakAll">www.merck.com/product/usa/pi_circulars/z/zocor/zocor_pi.pdf (Accessed on December 19, 2011).</li><li><a class="nounderline abstract_t">HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34:1279.</a></li><li><a class="nounderline abstract_t">Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol 2013; 29:1553.</a></li><li><a class="nounderline abstract_t">Patel AM, Shariff S, Bailey DG, et al. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Ann Intern Med 2013; 158:869.</a></li><li><a class="nounderline abstract_t">Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006; 114:2788.</a></li><li><a class="nounderline abstract_t">Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005; 84:377.</a></li><li class="breakAll">Craig Williams. Myopathy. In: Drug-Induced Diseases Prevention, Detection and Management, 2nd edition, James E. Tisdale, Douglas A. Miller (Eds), American Society of Health-System Pharmacists, Inc., Bethesda 2010. p.1017.</li><li><a class="nounderline abstract_t">Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 1988; 109:597.</a></li><li><a class="nounderline abstract_t">Guyton JR, Capuzzi DM. Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol 1998; 82:82U.</a></li><li><a class="nounderline abstract_t">Alsheikh-Ali AA, Karas RH. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). Am J Cardiol 2007; 99:379.</a></li><li><a class="nounderline abstract_t">Bays H. Safety of niacin and simvastatin combination therapy. Am J Cardiol 2008; 101:3B.</a></li><li><a class="nounderline abstract_t">Chatzizisis YS, Koskinas KC, Misirli G, et al. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010; 33:171.</a></li><li><a class="nounderline abstract_t">Martin J, Krum H. Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant? Drug Saf 2003; 26:13.</a></li><li><a class="nounderline abstract_t">Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319:24.</a></li><li><a class="nounderline abstract_t">Keogh A, Macdonald P, Kaan A, et al. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000; 19:529.</a></li><li><a class="nounderline abstract_t">Yee HS, Fong NT. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Ann Pharmacother 1998; 32:1030.</a></li><li><a class="nounderline abstract_t">Patel DN, Pagani FD, Koelling TM, et al. Safety and efficacy of atorvastatin in heart transplant recipients. J Heart Lung Transplant 2002; 21:204.</a></li><li><a class="nounderline abstract_t">Ayanian JZ, Fuchs CS, Stone RM. Lovastatin and rhabdomyolysis. Ann Intern Med 1988; 109:682.</a></li><li><a class="nounderline abstract_t">Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995; 333:664.</a></li><li><a class="nounderline abstract_t">Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341:498.</a></li><li><a class="nounderline abstract_t">Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16:569.</a></li><li><a class="nounderline abstract_t">Rosenson RS, Colantonio LD, Burkholder GA, et al. Trends in Utilization of Statin Therapy and Contraindicated Statin Use in HIV--Infected Adults Treated With Antiretroviral Therapy From 2007 Through 2015. J Am Heart Assoc 2018; 7:e010345.</a></li><li class="breakAll">Zocor (simvastatin) US prescribing information (revision 10/2012) available at NIH DailyMed website http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fdbfe194-b845-42c5-bb87-a48118bc72e7 (Accessed on March 08, 2013).</li><li class="breakAll">US Food and Drug Administration. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. February 28, 2012. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm (Accessed on February 28, 2012).</li><li><a class="nounderline abstract_t">Penzak SR, Chuck SK. Management of protease inhibitor-associated hyperlipidemia. Am J Cardiovasc Drugs 2002; 2:91.</a></li><li><a class="nounderline abstract_t">van der Lee M, Sankatsing R, Schippers E, et al. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther 2007; 12:1127.</a></li><li class="breakAll">Livalo (pitavastatin) US prescribing information. Available at NIH DailyMed website http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b3c41a2f-da77-4465-8af6-038006a7ea58 (Accessed on March 08, 2013).</li><li class="breakAll">FDA Drug Safety Communication: Interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury http://www.fda.gov/Drugs/DrugSafety/ucm293877.htm (Accessed on March 08, 2013).</li><li><a class="nounderline abstract_t">Wiggins BS, Lamprecht DG Jr, Page RL 2nd, Saseen JJ. Recommendations for Managing Drug-Drug Interactions with Statins and HIV Medications. Am J Cardiovasc Drugs 2017; 17:375.</a></li><li class="breakAll">www.fda.gov/cder/drug/InfoSheets/HCP/simvastatin_amiodaroneHCP.htm (Accessed on August 12, 2008).</li><li><a class="nounderline abstract_t">Reddy P, Ellington D, Zhu Y, et al. Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. Br J Clin Pharmacol 2011; 72:434.</a></li><li><a class="nounderline abstract_t">Holdaas H, Hagen E, Asberg A, et al. Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. Int J Clin Pharmacol Ther 2006; 44:163.</a></li><li><a class="nounderline abstract_t">Kantola T, Backman JT, Niemi M, et al. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000; 56:225.</a></li><li class="breakAll">Crestor (rosuvastatin) US prescribing information (revision 12/2012) available at NIH DailyMed website: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb0f3b5e-4bc6-41c9-66b9-6257e2513512 (Accessed on March 08, 2013).</li><li><a class="nounderline abstract_t">Holdaas H, Hartmann A, Stenstrøm J, et al. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995; 76:102A.</a></li><li><a class="nounderline abstract_t">Glueck CJ, Oakes N, Speirs J, et al. Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol 1992; 70:1.</a></li><li><a class="nounderline abstract_t">Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 1998; 81:368.</a></li><li><a class="nounderline abstract_t">Alayli G, Cengiz K, Cantürk F, et al. Acute myopathy in a patient with concomitant use of pravastatin and colchicine. Ann Pharmacother 2005; 39:1358.</a></li><li><a class="nounderline abstract_t">Kotanko P, Kirisits W, Skrabal F. Rhabdomyolysis and acute renal graft impairment in a patient treated with simvastatin, tacrolimus, and fusidic acid. Nephron 2002; 90:234.</a></li><li><a class="nounderline abstract_t">Wenisch C, Krause R, Fladerer P, et al. Acute rhabdomyolysis after atorvastatin and fusidic acid therapy. Am J Med 2000; 109:78.</a></li><li><a class="nounderline abstract_t">Yuen SL, McGarity B. Rhabdomyolysis secondary to interaction of fusidic acid and simvastatin. Med J Aust 2003; 179:172.</a></li><li><a class="nounderline abstract_t">Magee CN, Medani SA, Leavey SF, et al. Severe rhabdomyolysis as a consequence of the interaction of fusidic acid and atorvastatin. Am J Kidney Dis 2010; 56:e11.</a></li><li><a class="nounderline abstract_t">O'Mahony C, Campbell VL, Al-Khayatt MS, Brull DJ. Rhabdomyolysis with atorvastatin and fusidic acid. Postgrad Med J 2008; 84:325.</a></li><li><a class="nounderline abstract_t">Burtenshaw AJ, Sellors G, Downing R. Presumed interaction of fusidic acid with simvastatin. Anaesthesia 2008; 63:656.</a></li><li><a class="nounderline abstract_t">Kearney S, Carr AS, McConville J, et al. Rhabdomyolysis after co-prescription of statin and fusidic acid. BMJ 2012; 345:e6562.</a></li><li><a class="nounderline abstract_t">Karas RH, Kashyap ML, Knopp RH, et al. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs 2008; 8:69.</a></li><li><a class="nounderline abstract_t">Thompson PD, Zmuda JM, Domalik LJ, et al. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 1997; 46:1206.</a></li><li><a class="nounderline abstract_t">Coen PM, Flynn MG, Markofski MM, et al. Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage. Metabolism 2009; 58:1030.</a></li><li><a class="nounderline abstract_t">Kearns AK, Bilbie CL, Clarkson PM, et al. The creatine kinase response to eccentric exercise with atorvastatin 10 mg or 80 mg. Atherosclerosis 2008; 200:121.</a></li><li><a class="nounderline abstract_t">Allard NAE, Janssen L, Lagerwaard B, et al. Prolonged Moderate-Intensity Exercise Does Not Increase Muscle Injury Markers in Symptomatic or Asymptomatic Statin Users. J Am Coll Cardiol 2023; 81:1353.</a></li><li><a class="nounderline abstract_t">Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006; 119:400.</a></li><li><a class="nounderline abstract_t">Meador BM, Huey KA. Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve 2010; 42:469.</a></li><li><a class="nounderline abstract_t">Henderson CA, Gomez CG, Novak SM, et al. Overview of the Muscle Cytoskeleton. Compr Physiol 2017; 7:891.</a></li><li><a class="nounderline abstract_t">Hopewell JC, Offer A, Haynes R, et al. Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. Eur Heart J 2020; 41:3336.</a></li><li><a class="nounderline abstract_t">Taylor BA, Sanchez RJ, Jacobson TA, et al. Application of the Statin-Associated Muscle Symptoms-Clinical Index to a Randomized Trial on Statin Myopathy. J Am Coll Cardiol 2017; 70:1680.</a></li><li><a class="nounderline abstract_t">Thompson PD, Clarkson PM, Rosenson RS, National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. Am J Cardiol 2006; 97:69C.</a></li><li><a class="nounderline abstract_t">Sathasivam S, Lecky B. Statin induced myopathy. BMJ 2008; 337:a2286.</a></li><li><a class="nounderline abstract_t">Franc S, Dejager S, Bruckert E, et al. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther 2003; 17:459.</a></li><li><a class="nounderline abstract_t">Jacobson TA, Cheeley MK, Jones PH, et al. The STatin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapy. J Clin Lipidol 2019; 13:415.</a></li><li><a class="nounderline abstract_t">Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005; 165:2671.</a></li><li><a class="nounderline abstract_t">Mikus CR, Boyle LJ, Borengasser SJ, et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol 2013; 62:709.</a></li><li><a class="nounderline abstract_t">Giordano N, Senesi M, Mattii G, et al. Polymyositis associated with simvastatin. Lancet 1997; 349:1600.</a></li><li><a class="nounderline abstract_t">Goldman JA, Fishman AB, Lee JE, Johnson RJ. The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis. Arthritis Rheum 1989; 32:358.</a></li><li><a class="nounderline abstract_t">Vasconcelos OM, Campbell WW. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 2004; 30:803.</a></li><li><a class="nounderline abstract_t">Noël B, Cerottini JP, Panizzon RG. Atorvastatin-induced dermatomyositis. Am J Med 2001; 110:670.</a></li><li><a class="nounderline abstract_t">Khattak FH, Morris IM, Branford WA. Simvastatin-associated dermatomyositis. Br J Rheumatol 1994; 33:199.</a></li><li><a class="nounderline abstract_t">Hill C, Zeitz C, Kirkham B. Dermatomyositis with lung involvement in a patient treated with simvastatin. Aust N Z J Med 1995; 25:745.</a></li><li><a class="nounderline abstract_t">Rodriguez-Garcia JL, Serrano Commino M. Lovastatin-associated dermatomyositis. Postgrad Med J 1996; 72:694.</a></li><li><a class="nounderline abstract_t">Huynh T, Cordato D, Yang F, et al. HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions. Intern Med J 2002; 32:486.</a></li><li><a class="nounderline abstract_t">Grable-Esposito P, Katzberg HD, Greenberg SA, et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010; 41:185.</a></li><li><a class="nounderline abstract_t">Wu Y, Lach B, Provias JP, et al. Statin-associated Autoimmune Myopathies: A Pathophysiologic Spectrum. Can J Neurol Sci 2014; 41:638.</a></li><li><a class="nounderline abstract_t">Alshehri A, Choksi R, Bucelli R, Pestronk A. Myopathy with anti-HMGCR antibodies: Perimysium and myofiber pathology. Neurol Neuroimmunol Neuroinflamm 2015; 2:e124.</a></li><li><a class="nounderline abstract_t">Christopher-Stine L, Casciola-Rosen LA, Hong G, et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010; 62:2757.</a></li><li><a class="nounderline abstract_t">David WS, Chad DA, Kambadakone A, Hedley-Whyte ET. Case records of the Massachusetts General Hospital. Case 7-2012. A 79-year-old man with pain and weakness in the legs. N Engl J Med 2012; 366:944.</a></li><li><a class="nounderline abstract_t">Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011; 63:713.</a></li><li><a class="nounderline abstract_t">Villa L, Lerario A, Calloni S, et al. Immune-mediated necrotizing myopathy due to statins exposure. Acta Myol 2018; 37:257.</a></li><li><a class="nounderline abstract_t">Haroon M, Devlin J. A case of ANCA-associated systemic vasculitis induced by atorvastatin. Clin Rheumatol 2008; 27 Suppl 2:S75.</a></li><li><a class="nounderline abstract_t">Ruchala M, Szczepanek E, Puszczewicz M, et al. Not a graves' situation. Am J Med 2011; 124:210.</a></li><li><a class="nounderline abstract_t">Krivosic-Horber R, Dépret T, Wagner JM, Maurage CA. Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment. Eur J Anaesthesiol 2004; 21:572.</a></li><li><a class="nounderline abstract_t">Guis S, Bendahan D, Kozak-Ribbens G, et al. Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility. Arthritis Rheum 2003; 49:237.</a></li><li><a class="nounderline abstract_t">Rosenson RS, Miller K, Bayliss M, et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability. Cardiovasc Drugs Ther 2017; 31:179.</a></li><li><a class="nounderline abstract_t">Neal RC, Ferdinand KC, Ycas J, Miller E. Relationship of ethnic origin, gender, and age to blood creatine kinase levels. Am J Med 2009; 122:73.</a></li><li><a class="nounderline abstract_t">Brewster LM, Mairuhu G, Sturk A, van Montfrans GA. Distribution of creatine kinase in the general population: implications for statin therapy. Am Heart J 2007; 154:655.</a></li><li><a class="nounderline abstract_t">Joy TR, Monjed A, Zou GY, et al. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med 2014; 160:301.</a></li><li><a class="nounderline abstract_t">Allenbach Y, Mammen AL, Benveniste O, et al. 224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord 2018; 28:87.</a></li><li><a class="nounderline abstract_t">Mammen AL, Tiniakou E. Intravenous Immune Globulin for Statin-Triggered Autoimmune Myopathy. N Engl J Med 2015; 373:1680.</a></li><li><a class="nounderline abstract_t">Gupta A, Thompson PD. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis 2011; 215:23.</a></li><li><a class="nounderline abstract_t">Ahmed W, Khan N, Glueck CJ, et al. Low serum 25 (OH) vitamin D levels (&lt;32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 2009; 153:11.</a></li><li><a class="nounderline abstract_t">Awad K, Mikhailidis DP, Toth PP, et al. Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. Cardiovasc Drugs Ther 2017; 31:419.</a></li><li><a class="nounderline abstract_t">Newman CB, Preiss D, Tobert JA, et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol 2019; 39:e38.</a></li><li><a class="nounderline abstract_t">Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis 2015; 238:329.</a></li><li><a class="nounderline abstract_t">Qu H, Guo M, Chai H, et al. Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc 2018; 7:e009835.</a></li><li><a class="nounderline abstract_t">Cohen PA, Avula B, Khan IA. Variability in strength of red yeast rice supplements purchased from mainstream retailers. Eur J Prev Cardiol 2017; 24:1431.</a></li><li><a class="nounderline abstract_t">Mannarino MR, Ministrini S, Pirro M. Nutraceuticals for the treatment of hypercholesterolemia. Eur J Intern Med 2014; 25:592.</a></li><li><a class="nounderline abstract_t">Li Y, Jiang L, Jia Z, et al. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One 2014; 9:e98611.</a></li><li><a class="nounderline abstract_t">Banach M, Patti AM, Giglio RV, et al. The Role of Nutraceuticals in Statin Intolerant Patients. J Am Coll Cardiol 2018; 72:96.</a></li><li><a class="nounderline abstract_t">Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333:621.</a></li><li><a class="nounderline abstract_t">Yoshimura N, Oka T, Okamoto M, Ohmori Y. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1992; 53:94.</a></li><li><a class="nounderline abstract_t">Schrama YC, Hené RJ, de Jonge N, et al. Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients: an exercise provocation test. Transplantation 1998; 66:1175.</a></li><li><a class="nounderline abstract_t">Li PK, Mak TW, Chan TH, et al. Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia. Transplantation 1995; 60:652.</a></li><li><a class="nounderline abstract_t">Goldberg RB, Roth D. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine. Am J Cardiol 1995; 76:107A.</a></li><li><a class="nounderline abstract_t">Shitara Y, Maeda K, Ikejiri K, et al. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos 2013; 34:45.</a></li><li><a class="nounderline abstract_t">Duggan ST. Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia. Drugs 2012; 72:565.</a></li><li><a class="nounderline abstract_t">Li DQ, Kim R, McArthur E, et al. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. CMAJ 2015; 187:174.</a></li><li><a class="nounderline abstract_t">Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997; 80:608.</a></li><li><a class="nounderline abstract_t">Ellen RL, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998; 81:60B.</a></li><li><a class="nounderline abstract_t">Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J 1995; 16:5.</a></li><li><a class="nounderline abstract_t">Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004; 116:408.</a></li><li><a class="nounderline abstract_t">Ballantyne CM, Davidson MH. Possible differences between fibrates in pharmacokinetic interactions with statins. Arch Intern Med 2003; 163:2394.</a></li><li><a class="nounderline abstract_t">Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002; 301:1042.</a></li><li><a class="nounderline abstract_t">Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849.</a></li><li><a class="nounderline abstract_t">Geng Q, Ren J, Chen H, et al. Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials. Clin Exp Pharmacol Physiol 2013; 40:219.</a></li><li><a class="nounderline abstract_t">Guo J, Meng F, Ma N, et al. Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia. Am J Cardiol 2012; 110:1296.</a></li><li><a class="nounderline abstract_t">Spence JD, Munoz CE, Hendricks L, et al. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 1995; 76:80A.</a></li><li><a class="nounderline abstract_t">Noé J, Portmann R, Brun ME, Funk C. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 2007; 35:1308.</a></li><li><a class="nounderline abstract_t">Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993; 94:13.</a></li><li><a class="nounderline abstract_t">Rosenson RS, Frauenheim WA. Safety of combined pravastatin-gemfibrozil therapy. Am J Cardiol 1994; 74:499.</a></li><li><a class="nounderline abstract_t">Farnier M, Dejager S. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group. Am J Cardiol 2000; 85:53.</a></li><li><a class="nounderline abstract_t">Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003; 73:538.</a></li><li class="breakAll">www.fda.gov/Drugs/DrugSafety/ucm256581.htm (Accessed on March 15, 2013).</li><li><a class="nounderline abstract_t">Koumis T, Nathan JP, Rosenberg JM, Cicero LA. Strategies for the prevention and treatment of statin-induced myopathy: is there a role for ubiquinone supplementation? Am J Health Syst Pharm 2004; 61:515.</a></li><li><a class="nounderline abstract_t">Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007; 49:2231.</a></li><li><a class="nounderline abstract_t">Bouitbir J, Daussin F, Charles AL, et al. Mitochondria of trained skeletal muscle are protected from deleterious effects of statins. Muscle Nerve 2012; 46:367.</a></li><li><a class="nounderline abstract_t">Parker BA, Augeri AL, Capizzi JA, et al. Effect of statins on creatine kinase levels before and after a marathon run. Am J Cardiol 2012; 109:282.</a></li></ol></div><div id="topicVersionRevision">Topic 6833 Version 71.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12353951" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Can statins cause chronic low-grade myopathy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15572716" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24793443" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : An assessment by the Statin Muscle Safety Task Force: 2014 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28859793" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Optimizing Cholesterol Treatment in Patients With Muscle Complaints.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29878063" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26886523" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Statin-Associated Autoimmune Myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8463436" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15210526" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16003294" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26192349" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Statin therapy and plasma coenzyme Q10 concentrations--A systematic review and meta-analysis of placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11479481" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The effect of pravastatin and atorvastatin on coenzyme Q10.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8623738" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16286544" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Muscle coenzyme Q10 level in statin-related myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23287371" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19051066" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19665003" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Statins, fibrates and retinoic acid upregulate mitochondrial acylcarnitine carrier gene expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17992259" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28771594" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25694464" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12672737" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Statin-associated myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24952854" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A systematic review of statin-induced muscle problems in clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36049498" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19528564" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Narrative review: statin-related myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23183941" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effect of statins on skeletal muscle function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3055921" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Efficacy and long-term adverse effect pattern of lovastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1831006" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1951069" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Long-term safety and efficacy profile of simvastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8862101" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12639201" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3275891" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3275892" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2355431" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12622602" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Risk for myopathy with statin therapy in high-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15389652" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cytoskeletal myotoxicity from simvastatin and colchicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30057227" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in Stroke Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22658145" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24528687" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16453090" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22022768" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27754879" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14872552" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : "The Pink Sheet" FDC Reports</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12021218" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18997196" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Chevy Chase, MD</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18608105" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Are statin medications safe in patients with ALS?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18199832" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Dyslipidemia is a protective factor in amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15263088" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17059860" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : De novo cholesterol synthesis at the crossroads of adaptive response to extracellular stress through SREBP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12241896" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Statins, fibrates, and ocular myasthenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15596782" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Statin-associated exacerbation of myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12353945" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Statin-associated myopathy with normal creatine kinase levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8420287" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16864763" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Presymptomatic neuromuscular disorders disclosed following statin treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15298748" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : McArdle's disease diagnosed following statin-induced myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : McArdle disease unmasked by statin exposure</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16018797" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Statin-disclosed acid maltase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20147729" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Neuromuscular symptoms and elevated creatine kinase after statin withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15202093" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : [Worsening for using statin in carnitine palmityol transferase deficiency myopathy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16688722" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Sporadic rippling muscle disease unmasked by simvastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20368665" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Another side to statin-related side effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19670387" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Hyaline inclusion myopathy: unmasked by statin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19084404" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A case of asymptomatic cytoplasmic body myopathy revealed by sinvastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8148686" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Myxoedema revealed by simvastatin induced myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7604176" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pravastatin-associated myopathy. Report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27798247" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Rechallenging Statin Therapy in Veterans With Statin-Induced Myopathy Post Vitamin D Replenishment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25838999" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Statin Intolerance Because of Myalgia, Myositis, Myopathy, or Myonecrosis Can in Most Cases be Safely Resolved by Vitamin D Supplementation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25464233" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18946323" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Genetic predisposition to statin myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18650507" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : SLCO1B1 variants and statin-induced myopathy--a genomewide study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19833260" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The SLCO1B1*5 genetic variant is associated with statin-induced side effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19940267" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Human skeletal muscle drug transporters determine local exposure and toxicity of statins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19940267" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Human skeletal muscle drug transporters determine local exposure and toxicity of statins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23444397" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24267801" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23778904" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17159064" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Risks associated with statin therapy: a systematic overview of randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16267412" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Rhabdomyolysis: an evaluation of 475 hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16267412" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Rhabdomyolysis: an evaluation of 475 hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3421570" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Lovastatin, nicotinic acid, and rhabdomyolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9915667" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Treatment of hyperlipidemia with combined niacin-statin regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17261402" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18375239" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Safety of niacin and simvastatin combination therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20158283" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12495360" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3288867" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10867332" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9793596" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11834348" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Safety and efficacy of atorvastatin in heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3421582" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Lovastatin and rhabdomyolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7637734" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10441607" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Drug treatment of lipid disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11873000" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30526249" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Trends in Utilization of Statin Therapy and Contraindicated Statin Use in HIV--Infected Adults Treated With Antiretroviral Therapy From 2007 Through 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30526249" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Trends in Utilization of Statin Therapy and Contraindicated Statin Use in HIV--Infected Adults Treated With Antiretroviral Therapy From 2007 Through 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30526249" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Trends in Utilization of Statin Therapy and Contraindicated Statin Use in HIV--Infected Adults Treated With Antiretroviral Therapy From 2007 Through 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14727985" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Management of protease inhibitor-associated hyperlipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18018771" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18018771" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18018771" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28364370" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Recommendations for Managing Drug-Drug Interactions with Statins and HIV Medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28364370" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Recommendations for Managing Drug-Drug Interactions with Statins and HIV Medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21501216" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625985" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10952477" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Effect of fluconazole on plasma fluvastatin and pravastatin concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10952477" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Effect of fluconazole on plasma fluvastatin and pravastatin concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7604781" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1615846" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9468088" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Rhabdomyolysis after taking atorvastatin with gemfibrozil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15914514" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Acute myopathy in a patient with concomitant use of pravastatin and colchicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11818715" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Rhabdomyolysis and acute renal graft impairment in a patient treated with simvastatin, tacrolimus, and fusidic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10991749" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Acute rhabdomyolysis after atorvastatin and fusidic acid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12885276" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Rhabdomyolysis secondary to interaction of fusidic acid and simvastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20888103" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Severe rhabdomyolysis as a consequence of the interaction of fusidic acid and atorvastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18644925" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Rhabdomyolysis with atorvastatin and fusidic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18477279" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Presumed interaction of fusidic acid with simvastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23047962" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Rhabdomyolysis after co-prescription of statin and fusidic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18422390" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9322808" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Lovastatin increases exercise-induced skeletal muscle injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19411087" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18261731" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : The creatine kinase response to eccentric exercise with atorvastatin 10 mg or 80 mg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37019582" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Prolonged Moderate-Intensity Exercise Does Not Increase Muscle Injury Markers in Symptomatic or Asymptomatic Statin Users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16651050" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Clinical perspectives of statin-induced rhabdomyolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20878737" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Statin-associated myopathy and its exacerbation with exercise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28640448" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Overview of the Muscle Cytoskeleton.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32702748" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28935043" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Application of the Statin-Associated Muscle Symptoms-Clinical Index to a Randomized Trial on Statin Myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16581332" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : An assessment of statin safety by muscle experts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18988647" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Statin induced myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15107601" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : A comprehensive description of muscle symptoms associated with lipid-lowering drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31113745" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : The STatin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16344427" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Outcomes in 45 patients with statin-associated myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23583255" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Simvastatin impairs exercise training adaptations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9174565" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Polymyositis associated with simvastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2930608" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15389654" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11388341" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Atorvastatin-induced dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8162495" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Simvastatin-associated dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8770347" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Dermatomyositis with lung involvement in a patient treated with simvastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8944218" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Lovastatin-associated dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12380704" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19813188" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Immune-mediated necrotizing myopathy associated with statins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25373816" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Statin-associated Autoimmune Myopathies: A Pathophysiologic Spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26090508" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Myopathy with anti-HMGCR antibodies: Perimysium and myofiber pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20496415" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22397657" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Case records of the Massachusetts General Hospital. Case 7-2012. A 79-year-old man with pain and weakness in the legs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21360500" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30944904" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Immune-mediated necrotizing myopathy due to statins exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18839266" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : A case of ANCA-associated systemic vasculitis induced by atorvastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21396501" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Not a graves' situation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15318472" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12687516" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28421332" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19114174" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Relationship of ethnic origin, gender, and age to blood creatine kinase levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17892987" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Distribution of creatine kinase in the general population: implications for statin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24737272" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : N-of-1 (single-patient) trials for statin-related myalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29221629" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : 224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26488714" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Intravenous Immune Globulin for Statin-Triggered Autoimmune Myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21185021" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : The relationship of vitamin D deficiency to statin myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19100953" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Low serum 25 (OH) vitamin D levels (&lt;32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28741244" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30580575" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25545331" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30371340" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28641460" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Variability in strength of red yeast rice supplements purchased from mainstream retailers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24997485" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Nutraceuticals for the treatment of hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24897342" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29957236" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : The Role of Nutraceuticals in Statin Intolerant Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7637722" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Effect of pravastatin on outcomes after cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1733092" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : The effects of pravastatin on hyperlipidemia in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9825814" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients: an exercise provocation test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7570971" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7604782" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23115084" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22356292" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25534598" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9294990" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9526816" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7737222" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15006590" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Current overview of statin-induced myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14581261" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Possible differences between fibrates in pharmacokinetic interactions with statins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12023536" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Mechanistic studies on metabolic interactions between gemfibrozil and statins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16310551" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23324122" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22840347" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7604806" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Pharmacokinetics of the combination of fluvastatin and gemfibrozil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470528" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8420296" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8059735" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Safety of combined pravastatin-gemfibrozil therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11078237" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12811363" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12811363" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15018231" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Strategies for the prevention and treatment of statin-induced myopathy: is there a role for ubiquinone supplementation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17560286" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : The role of coenzyme Q10 in statin-associated myopathy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22907227" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Mitochondria of trained skeletal muscle are protected from deleterious effects of statins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22036108" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Effect of statins on creatine kinase levels before and after a marathon run.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
